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Abstract
Each mammalian cell type has a unique gene expression pattern that supports its specialized function.
Mutations in factors that regulate gene expression can disrupt normal function and cause human disease,
though the mechanistic consequences of these defects are often unknown. Here, we address how alterations in
the transcription factor GATA1 lead to distinct hematologic disorders by combining structural, biochemical,
and genomic approaches with gene complementation systems that examine GATA1 function in biologically
relevant cellular contexts. We first investigated missense mutations in the GATA1 N-terminal zinc finger (NF)
and found that NF mutations impair association with essential GATA1 cofactors. Several NF mutations
diminish FOG1 binding, resulting in greatly reduced transcriptional activation and repression. This severely
impairs erythroid and megakaryocyte maturation and correlates with pronounced clinical phenotypes.
Notably, clinical severity parallels the degree of FOG1 disruption. Unexpectedly, NF mutations shown to
disrupt DNA binding of GATA1 in vitro did not measurably affect target gene occupancy in vivo. Rather, one
of these falls into a subset of mutations that diminish TAL1 complex binding. Reduced association with the
TAL1 complex moderately impairs transcriptional activation, resulting in subtle defects in erythroid and
megakaryocyte development that correlate with relatively mild disease presentations. Remarkably, different
substitutions at the same amino acid position can selectively inhibit TAL1 complex or FOG1 binding,
producing distinct cellular and clinical phenotypes. We next examined splice site mutations in the second
exon of GATA1 that lead to the expression of an amino-truncated protein called GATA1 short (GATA1s). We
found that GATA1s was significantly impaired in binding to erythroid-specific target genes, while occupancy
at megakaryocyte-specific genes was normal. This results in a strongly diminished erythroid gene expression
program and inhibits erythroid maturation, similar to the phenotype observed in patients. In concert, our
findings uncover novel molecular mechanisms that link genetic defects in GATA1 to cellular and human
phenotypes. Applying this knowledge to the clinic should improve patient diagnosis, classification, and
treatment. More broadly, this work highlights the power of gene complementation assays for elucidating the
underlying basis of disease, and serves as a model for the study of other disease-causing mutations.
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ABSTRACT 
 
DISSECTING MOLECULAR PATHWAYS THAT UNDERLIE DISEASE-CAUSING GATA1 
MUTATIONS 
Amy E. Campbell 
Gerd A. Blobel 
 
Each mammalian cell type has a unique gene expression pattern that supports its specialized 
function. Mutations in factors that regulate gene expression can disrupt normal function and 
cause human disease, though the mechanistic consequences of these defects are often 
unknown. Here, we address how alterations in the transcription factor GATA1 lead to distinct 
hematologic disorders by combining structural, biochemical, and genomic approaches with gene 
complementation systems that examine GATA1 function in biologically relevant cellular contexts. 
We first investigated missense mutations in the GATA1 N-terminal zinc finger (NF) and found that 
NF mutations impair association with essential GATA1 cofactors. Several NF mutations diminish 
FOG1 binding, resulting in greatly reduced transcriptional activation and repression. This severely 
impairs erythroid and megakaryocyte maturation and correlates with pronounced clinical 
phenotypes. Notably, clinical severity parallels the degree of FOG1 disruption. Unexpectedly, NF 
mutations shown to disrupt DNA binding of GATA1 in vitro did not measurably affect target gene 
occupancy in vivo. Rather, one of these falls into a subset of mutations that diminish TAL1 
complex binding. Reduced association with the TAL1 complex moderately impairs transcriptional 
activation, resulting in subtle defects in erythroid and megakaryocyte development that correlate 
with relatively mild disease presentations. Remarkably, different substitutions at the same amino 
acid position can selectively inhibit TAL1 complex or FOG1 binding, producing distinct cellular 
and clinical phenotypes. We next examined splice site mutations in the second exon of GATA1 
that lead to the expression of an amino-truncated protein called GATA1 short (GATA1s). We 
found that GATA1s was significantly impaired in binding to erythroid-specific target genes, while 
v 
 
occupancy at megakaryocyte-specific genes was normal. This results in a strongly diminished 
erythroid gene expression program and inhibits erythroid maturation, similar to the phenotype 
observed in patients. In concert, our findings uncover novel molecular mechanisms that link 
genetic defects in GATA1 to cellular and human phenotypes. Applying this knowledge to the clinic 
should improve patient diagnosis, classification, and treatment. More broadly, this work highlights 
the power of gene complementation assays for elucidating the underlying basis of disease, and 
serves as a model for the study of other disease-causing mutations. 
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CHAPTER 1. INTRODUCTION 
 
Eukaryotic transcriptional regulation 
During mammalian development, a single fertilized egg undergoes numerous divisions to 
generate the trillions of cells that make up a mature organism. Although nearly all of these cells 
contain the same genetic material, they comprise hundreds of different cell types that carry out 
highly specialized functions. For example, only pancreatic β-cells produce the peptide hormone 
insulin to regulate blood glucose levels, while only red blood cells make the oxygen transport 
protein hemoglobin. This exquisite specialization is achieved by precisely controlling which genes 
are turned on or off in each cell, thereby establishing a unique gene expression program that 
determines cellular function and identity.  
The human genome contains over 25,000 functional gene products (Djebali et al., 2012), and 
there are many regulatory mechanisms in place to govern which subset of these genes are 
expressed in a particular cell at any given time. This regulatory control is exercised at numerous 
steps, including when and how often a gene is transcribed into RNA, how the RNA is processed, 
where the RNA is localized, stability of the RNA, RNA translation, and by selectively activating or 
deactivating a protein once it is made. Normal growth requires this regulation to be spatially and 
temporally accurate, and defects can lead to aberrant development and disease.  
While expression can be regulated at any of the steps mentioned above, for most genes the 
control of transcription is paramount. Proper transcriptional control ensures that no unnecessary 
intermediates are synthesized, and therefore best conserves cellular resources. The fundamental 
mechanisms of transcriptional regulation were elucidated over fifty years ago (Jacob and Monod, 
1961), and subsequent studies have refined our understanding and established a well-accepted 
paradigm (Figure 1.1). In the contemporary model, eukaryotic transcription is a precisely timed 
event, with regulation occurring at multiple points through the combinatorial and synergistic 
actions of a host of molecules.  
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Transcription on DNA 
Several DNA regulatory elements must function cooperatively in order to achieve maximal 
rates of transcription by RNA polymerase II (Pol II). These include: 1) core promoter elements, 
which are bound by Pol II, 2) promoter proximal elements, which are occupied by proteins that 
assist the binding of Pol II to the promoter, and 3) distal regulatory elements such as enhancers, 
silencers, and insulators, which act on the promoter from a considerable distance to modulate 
expression (Maston et al., 2006). Promoters are typically influenced by multiple distal regulatory 
elements, and no two genes have the exact same complement of elements (Tjian, 1995). This 
allows for a combinatorial control that exponentially increases the possible number of unique 
expression patterns.  
The DNA regulatory elements described above contain recognition sites for sequence-
specific DNA-binding proteins called transcription factors, which function either to augment or 
suppress the rate of transcription. Transcription factors can be classified into two groups, general 
and tissue-specific. General transcription factors (GTFs) are necessary for transcription and 
include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (Matsui et al., 1980). They assemble onto 
the core promoter in an ordered fashion to form a preinitiation complex (PIC) that directs Pol II to 
the transcription start site (Orphanides et al., 1996). However, GTFs alone are only sufficient to 
direct basal levels of activity; transcription is greatly stimulated or repressed by the presence of 
tissue-specific transcription factors. These transcription factors accelerate transcription by 
increasing PIC formation through direct interactions with GTFs, promoting transcription initiation 
or elongation, or recruiting activities that modify chromatin structure (see below). They can block 
transcription by inhibiting PIC assembly, impeding or competing for a particular DNA element, or 
by changing the chromatin state (Lee and Young, 2000). Multiple tissue-specific transcription 
factors can bind cooperatively to a single regulatory element (Berman et al., 2002), a mechanism 
that further expands the potential for distinct expression patterns. In an additional layer of 
regulation, the activities of tissue-specific transcription factors are often modulated by the action 
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of cofactors. Cofactors do not directly bind DNA, but are instead recruited to regulatory elements 
via protein-protein interactions with a bound transcription factor where they function to enhance or 
repress transcriptional activity through the same mechanisms used by transcription factors 
themselves (Maston et al., 2006). 
Once Pol II is recruited to the promoter by transcription factors, the promoter DNA is 
unwound and transcription initiates. Pol II first produces small, abortive RNAs, but after it attains a 
stable hold on the DNA and generates a slightly longer RNA molecule, it is able to clear the 
promoter and engage in transcript elongation (Fuda et al., 2009). At some genes Pol II continues 
to productively elongate through the gene body to create a full-length transcript. However, at 
many other loci transcription proceeds only a short distance (20-50 base pairs) before Pol II 
pauses (Core et al., 2008; Muse et al., 2007; Zeitlinger et al., 2007). Pausing is achieved through 
the action of DSIF and NELF, which bind and inhibit the polymerase (Wada et al., 1998; 
Yamaguchi et al., 1999). Pause release and productive elongation occur only once a robust 
positive signal in the form of the protein P-TEFb arrives. P-TEFb modifies DSIF and NELF to 
relieve their negative influence, and also modifies Pol II itself (Fujinaga et al., 2004; Marshall et 
al., 1996; Yamada et al., 2006). This step is increasingly recognized as a major mechanism in 
gene expression regulation.  
As Pol II traverses the gene coding region, factors such as TFIIS, ELL, Elongin, FACT, and 
PAF regulate its processivity (Bradsher et al., 1993; Kim et al., 2010; Orphanides et al., 1998; 
Reines et al., 1989; Shilatifard et al., 1996). This elongation machinery additionally interacts with 
proteins involved in RNA capping and splicing to achieve co-transcriptional processing of the 
nascent RNA transcript (Montes et al., 2012). When Pol II reaches the end of a gene, it 
transcribes through a conserved DNA element known as a polyadenylation signal. This first slows 
and then pauses Pol II, which leads to cleavage and modification of the transcript (Connelly and 
Manley, 1988; Orozco et al., 2002). This process of transcription termination is mediated by a 
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number of factors, including CPSF, Cstf, Xrn2, and poly A polymerase (Shandilya and Roberts, 
2012). 
 
Transcription on chromatin 
Eukaryotic transcription does not occur on a naked DNA template. Rather, genomic DNA is 
packaged into a proteinacious structure known as chromatin. Chromatin allows the approximately 
two meters of DNA in each cell to be compacted enough to fit the confines of a nucleus that is 
~10 µm in diameter. The basic unit of chromatin, the nucleosome, consists of 147 base pairs of 
DNA wrapped around a protein octamer containing two each of the core histones H2A, H2B, H3, 
and H4 (Luger et al., 1997). Nucleosomes are connected by stretches of unwrapped linker DNA, 
which varies in length and is bound by an additional histone, linker histone H1 or H5. This level of 
compaction results in an 11 nm fiber reminiscent of a “beads-on-a-string” structure (Olins and 
Olins, 1974; Woodcock et al., 1976). These fibers are then further condensed, with maximal 
packaging into chromosomes achieved during cell division.  
Significant obstacles to transcription arise as a consequence of compacting DNA into 
chromatin. DNA accessibility is greatly restricted and therefore transcription factors are blocked 
from binding target sequences, Pol II is prevented from traveling along the gene, and transcription 
is inhibited. For transcription to occur, chromatin structure must be altered to allow the 
appropriate machinery access to DNA. The modification of chromatin is carried out by two 
classes of enzymes – ATP-dependent chromatin remodelers and histone modifiers. By 
necessitating these additional layers of regulatory complexity, the packaging of DNA into 
chromatin further expands the potential for unique gene expression patterns and allows for more 
finely tuned transcriptional outputs.  
ATP-dependent chromatin remodelers use the energy of ATP hydrolysis to non-covalently 
restructure and reposition nucleosomes, thereby altering DNA accessibility to either promote or 
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repress transcription. The SWI/SNF (mating type switching/sucrose non-fermenting) family of 
remodelers is generally linked to transcriptional activation, while the ISWI (imitation switch) family 
typically acts to silence transcription (Saha et al., 2006). In contrast, the CHD (chromodomain 
helicase DNA-binding) and INO80 (inositol auxotroph 80) families play roles in both activation and 
repression (Conaway and Conaway, 2009; Murawska and Brehm, 2011). The importance of 
remodelers is illustrated by the INF-β locus, where SWI/SNF slides promoter nucleosomes to 
activate transcription, which is critical for antiviral immunity (Lomvardas and Thanos, 2001; Zhang 
et al., 2008). 
Histone modifiers covalently alter nucleosomal histones by adding or removing specific 
chemical groups. The enzymes that attach these groups are referred to as “writers”, and those 
that remove them are called “erasers”. At least ten distinct classes of modification have been 
described, including acetylation, methylation, phosphorylation, ubiquitylation, sumolyation, and 
ribosylation (Tan et al., 2011). Most modifications are dynamic, and they adopt predictable 
genomic distributions that can be used to define specific cellular processes (Rando and Chang, 
2009). For example, trimethylation of lysine 36 on histone H3, added by the methyltransferase 
SETD2 and removed by the demethylase JMJD2, is found in the coding region of actively 
transcribed genes (Klose et al., 2006; Kouzarides, 2007; Sun et al., 2005).  
Histone modifications serve two main functions. First, they can enhance or weaken histone-
histone or histone-DNA contacts to directly alter DNA accessibility. In this regard, histone 
acetylation is thought to directly unfold chromatin by neutralizing positively charged lysine 
residues that typically contact negatively charged DNA. Indeed, acetylation of lysine 16 on 
histone H4 impedes 11 nm fiber compaction in vitro (Shogren-Knaak et al., 2006). Second, 
histone modifications can indirectly alter DNA accessibility by creating interaction surfaces that 
allow or prevent the docking of effector molecules, called “readers”, which then go on to alter 
chromatin. “Readers” recognize specific modifications via specialized structural folds such as 
bromo-, chromo-, and PHD domains (Yun et al., 2011). For example, the PHD domain-containing 
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protein ING2 binds trimethylated lysine 4 on histone H3 and recruits the Sin3a-HDAC1 
deacetylase complex to silence proliferation genes after DNA-damage exposure (Shi et al., 
2006). As with remodelers, histone modifications can result in either the activation or repression 
of gene transcription.  
 
Transcription in human disease 
Many clinical phenotypes, from cancer to diabetes to cardiovascular disease, are caused by 
mutations in transcriptional regulators. Disease-causing mutations can occur within DNA 
regulatory elements. For example, a single nucleotide change at the GP1Bβ proximal promoter 
disrupts the binding of a tissue-specific transcription factor, which impairs transcriptional 
activation and leads to the bleeding disorder Bernard-Soulier Syndrome (Ludlow et al., 1996). 
More recent analyses are revealing the major role that sequence changes in enhancer elements 
play in misregulation of gene expression and disease (Maurano et al., 2012). A clear illustration of 
this phenomenon is seen with dysregulated SHH gene expression and limb malformation, where 
mutations in a SHH enhancer cause preaxial polydactyly (Lettice et al., 2003).  
Disease-causing mutations are also found in the genes encoding transcription factors and 
their cofactors. The GTF TFIIH is mutated in xeroderma pigmentosum (Lehmann, 2001), and 
numerous tissue-specific transcription factors have been linked to human disorders (Lee and 
Young, 2013). Examples in this latter category include heart disease caused by NKX2-5 
mutations (Schott et al., 1998), diabetes caused by mutations in HNF4α (Yamagata et al., 1996), 
and the cancer-predisposing Li-Fraumeni syndrome caused by TP53 mutations (Varley, 2003). 
Similarly, alterations to the transcriptional cofactor Mediator have been implicated in cancer 
(Barbieri et al., 2012) and neurological disorders (Kaufmann et al., 2010; Risheg et al., 2007; 
Schwartz et al., 2007).  
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Finally, defects in chromatin-modifying and -binding proteins can lead to disease. For 
example, the ATP-dependent chromatin remodeler SWI/SNF is mutated in many cancers (Wilson 
and Roberts, 2011), the methylation “eraser” UTX is mutated in acute lymphoblastic leukemia 
(Mar et al., 2012), and the acetyl “readers” BRD3 and BRD4 are rearranged in NUT midline 
carcinoma (French et al., 2008).   
Given its central place in human disease, modulating transcription for therapeutic benefit is 
an important goal of biomedical research. Approximately 10% of currently prescribed drugs target 
transcription factors of the nuclear receptor family (Overington et al., 2006), though non-ligand-
binding transcription factors have proven more recalcitrant to targeting and drug development 
here has been slower. There is a burgeoning effort to develop small molecules against other 
chromatin proteins (Dawson and Kouzarides, 2012), and early success with bromodomain 
inhibitors (Dawson et al., 2011; Filippakopoulos et al., 2010; Nicodeme et al., 2010) makes this 
an exciting area of work. Additionally, the development of engineered zinc finger, transcription 
activator-like effector (TALE), and RNA-guided CRISPR/Cas DNA-binding proteins has opened 
the door to targeted activation or repression of individual misregulated gene loci to ameliorate or 
reverse disease symptoms (Gao et al., 2013; Garriga-Canut et al., 2012; Gilbert et al., 2013; 
Wilber et al., 2010). Genome editing to correct disease-causing mutations is also possible using 
these engineered systems (Gaj et al., 2013).  
 
Hematopoiesis 
Hematopoiesis is the process by which mature blood cells are formed from the self-renewal and 
differentiation of pluripotent hematopoietic stem cells (HSCs). It is a complex, multistage event 
that begins during embryonic development and continues throughout adulthood. In mammals, 
hematopoiesis occurs in two waves: first in the fetal yolk sac, placenta, and aorta-gonad-
mesonephros region (primitive hematopoiesis), and later in the fetal liver and bone marrow 
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(definitive hematopoiesis), where it continues throughout adulthood. At each of these sites, 
extrinsic signals instruct HSCs to develop into multipotent progenitors, which become committed 
precursors that eventually differentiate into mature, specialized cell types (Figure 1.2). These 
mature cells are short lived, and therefore blood is being constantly regenerated as billions of old 
cells are replenished with new ones each day (Rieger and Schroeder, 2012). 
 
Erythrocyte and megakaryocyte development 
Red blood cells (also referred to as erythroid cells or erythrocytes) and megakaryocytes are 
closely related hematopoietic cell types. They arise from a common megakaryocyte-erythroid 
progenitor (MEP) and require some of the same transcriptional regulators for proper 
development. However, they carry out very different functions. Erythrocytes transport oxygen to 
all the tissues of the body, while megakaryocytes generate platelets (also referred to as 
thrombocytes), which play an essential role in blood clotting and wound healing.  
When a MEP is exposed to erythroid stimulating signals, it develops into a slowly 
proliferating, committed erythroid precursor called a BFU-E (burst forming unit-erythroid). BFU-Es 
further differentiate into rapidly dividing CFU-E (colony forming unit-erythroid). In the presence of 
the cytokine erythropoietin (EPO), CFU-Es undergo terminal erythroid maturation. Now, 
morphologically distinct cells are produced with each successive mitosis, beginning with 
proerythroblasts and followed by basophilic, polychromatic, and orthochromatic erythroblasts. 
Orthochromatic erythroblasts expel their nuclei to generate reticulocytes, which enter the 
circulation and finally become erythrocytes. This ordered maturation is accompanied by drastic 
cellular changes, including nuclear condensation, decreased cell size, hemoglobinization, and 
changes in membrane organization. The resulting erythrocytes are anucleate ~7 µm diameter 
biconcave disks chock-full of hemoglobin. Their small size and distinctive shape allows them to 
squeeze through microcapillaries and creates a large surface area for efficient gas exchange. 
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After ~100 days in circulation, aging erythrocytes are phagocytosed, thus removing old and 
defective cells (Dzierzak and Philipsen, 2013; Hattangadi et al., 2011).  
In contrast, when a MEP is exposed to megakaryocyte stimulating signals, it develops into a 
committed megakaryocytic precursor called a BFU-Meg (burst forming unit-megakaryocyte). 
BFU-Meg cells give rise to CFU-Meg (colony forming unit-megakaryocyte), which undergo 
terminal maturation to produce promegakaryoblasts, megakaryoblasts, promegakaryocytes, and 
megakaryocytes. Unlike in erythroid development, terminal megakaryocyte maturation does not 
involve cell division. Instead, distinct cell stages arise through endomitosis and cytoplasmic 
maturation, which increase DNA content and cell size. By undergoing repeated cycles of DNA 
replication without division, a diploid (2n) promegakaryoblast becomes a 256n megakaryocyte. 
(Most megakaryocytes undergo three endomitoses and are 16n.) Concurrently, the cytoplasm 
grows and fills with specialized organelles and invaginated membrane. The resulting 
megakaryocyte is big (~50-100 µm diameter) and contains a single, large, multilobulated, 
polyploid nucleus surrounded by a complex cytoplasmic network. This network is then divided up 
and packaged into platelets via the formation of long, thin filament extensions called proplatelets. 
After platelet release, the megakaryocyte (composed mostly of the remaining nucleus) undergoes 
apoptosis and is consumed by macrophages (Deutsch and Tomer, 2006; Pang et al., 2005). 
Erythrocyte and megakaryocyte development are regulated by a relatively small number of 
tissue-specific transcription factors and cofactors. These factors function to activate lineage-
specific genes and repress genes associated with immature, proliferative states and alternative 
cell fates. Some factors, like GATA1 and FOG1, are required for the maturation of both cell types. 
Others are lineage-specific. For example, EKLF is important for erythroid but not megakaryocyte 
development, while the opposite is true for Fli1 (Orkin and Zon, 2008). However, as of yet, no 
single unique factor has been identified that determines lineage choice of the MEP.  
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Transcription factor GATA1 
The transcription factor GATA1 was discovered in the late 1980s as researchers explored 
mechanisms that control hemoglobin synthesis (Evans and Felsenfeld, 1989; Evans et al., 1988; 
Tsai et al., 1989; Wall et al., 1988). Soon after, loss-of-function studies established GATA1 as 
absolutely critical for both erythrocyte and megakaryocyte development. Whole-body deletion of 
GATA1 in mice leads to death around embryonic day 11.5 due to a lack of mature erythroid cells 
(Fujiwara et al., 1996). A block in differentiation and apoptosis at the proerythroblast stage 
account for the failure to produce mature red blood cells (Pevny et al., 1995; Weiss and Orkin, 
1995; Weiss et al., 1994). The early death of GATA1-null embryos precludes direct study of their 
megakaryocytes. However, tissue-specific ablation of GATA1 in murine megakaryocytes 
markedly decreases platelet production by causing maturation arrest and hyperproliferation of 
immature cells (Shivdasani et al., 1997; Vyas et al., 1999).  
In addition to insights gleaned from animals, much has been learned about the role of GATA1 
in erythroid and megakaryocyte development through the use of two cell lines, GATA1-null 
erythroid (G1E) and GATA1-null megakaryocyte-erythroid (G1ME). Both G1E and G1ME cells 
were derived from GATA1-null murine embryonic stem cells. G1E cells proliferate as 
proerythroblasts and undergo terminal erythroid differentiation upon restoration of GATA1 
function (Weiss et al., 1997). A G1E-ER subclone of these cells was engineered to stably express 
a conditional form of GATA1 (GATA1 fused to the ligand-binding domain of the estrogen receptor, 
GATA1-ER) that imparts estradiol (E2)-dependent erythroid maturation in a manner largely 
reproducing that of wild-type cells (Pilon et al., 2011; Tsang et al., 1997; Welch et al., 2004). 
G1ME cells self-renew in culture as bipotential megakaryocyte-erythroid progenitors and undergo 
terminal differentiation towards the erythroid and megakaryocyte lineages when reconstituted with 
GATA1 and grown in the appropriate cytokine environment (Stachura et al., 2006). These easily 
manipulatable systems enable the study of GATA1 in its natural context at physiological 
expression levels and provide a homogenous cellular and genetic background that reveals subtle 
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defects. Further, large amounts of material can be readily obtained for biochemical studies. Using 
these gene complementation systems, valuable insights have been gained regarding 
structure/function relationships (Weiss et al., 1997), post-translational modifications (Hung et al., 
1999; Lee et al., 2009), novel target genes (Kihm et al., 2002; Shirihai et al., 2000), mechanisms 
of cell cycle regulation (Rylski et al., 2003), changes in chromatin structure (Jing et al., 2008; 
Letting et al., 2003; Vakoc et al., 2005), and lineage choice (Chou et al., 2009). 
GATA1 promotes the maturation of erythrocytes and megakaryocytes by activating the 
transcription of lineage-specific genes and silencing the transcription of genes associated with 
immature, proliferative states and alternative cell fates (Ferreira et al., 2005). This task is 
accomplished through four functional domains: two highly conserved zinc finger domains of the 
C4 (Cys-X2-Cys-X17-Cys-X2-Cys) type and two activation domains (Figure 1.3). The C-terminal 
zinc finger (CF) is the primary mediator of DNA binding, recognizing the canonical GATA1 
consensus sequence (A/T)GATA(A/G) (Evans et al., 1988; Martin and Orkin, 1990). The N-
terminal zinc finger (NF) stabilizes DNA binding at canonical motifs and is required for GATA1 to 
bind non-canonical GATC and palindromic ATC(A/T)GATA(A/G) motifs in vitro (Martin and Orkin, 
1990; Newton et al., 2001; Trainor et al., 1996). The surface of GATA1 that contacts DNA has 
been defined structurally (Omichinski et al., 1993). In addition to binding DNA, the zinc finger 
domains mediate protein-protein interactions (discussed below). In particular, the NF directly 
binds to the essential cofactors FOG1 and LMO2. The N- and C-terminal activation domains (the 
NAD and CAD) also mediate protein interactions (discussed below). Defined by their ability to 
confer transcriptional activation in reporter assays in heterologous cells (Martin and Orkin, 1990), 
the NAD and CAD play important, if poorly understood, roles in vivo (Kaneko et al., 2012; Kuhl et 
al., 2005; Li et al., 2005; Muntean and Crispino, 2005; Shimizu et al., 2001; 2009) likely by 
recruiting specific coregulators to GATA1 target genes. 
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GATA1-associated proteins 
GATA1 interacts with a number of other proteins, both tissue-specific and ubiquitously 
expressed, which modulate its activity and help ensure lineage-specific gene expression. 
Establishing which of these interactions are functionally significant, determining the mechanisms 
through which they modulate GATA1 activity, and understanding how they relate to one another 
is an ongoing challenge.  
 
FOG1 
Friend of GATA1 (FOG1) is a hematopoietic-specific protein that was first identified as a 
GATA1 binding partner by yeast two-hybrid screen (Tsang et al., 1997). Although FOG1 contains 
nine zinc finger domains, it does not bind DNA. Instead, FOG1 interacts directly with the GATA1 
NF via its first, fifth, sixth, and ninth zinc fingers (Fox et al., 1998; 1999; Tsang et al., 1997). The 
surface of the GATA1 NF that contacts FOG1 has been defined structurally, and is distinct from 
the surface that binds DNA (Liew et al., 2005). Like GATA1, FOG1 is required for normal 
erythroid and megakaryocyte differentiation (Tsang et al., 1997; 1998). Disrupting the GATA1-
FOG1 interaction impairs normal maturation of these lineages (Chang et al., 2002; Crispino et al., 
1999), interrupts activation and repression of most GATA1-regulated genes (Johnson et al., 
2007), and results in aberrant activation of mast cell-specific genes (Chlon et al., 2012; Gregory 
et al., 2010). Importantly, the clinical relevance of the GATA1-FOG1 interaction was made clear 
by the identification of patients with anemia and thrombocytopenia who have GATA1 mutations 
that impair FOG1 binding (Nichols et al., 2000) (discussed below). In addition to the functions 
described above, FOG1 modulates GATA1 chromatin occupancy at a subset of genomic sites 
(Chlon et al., 2012; Letting et al., 2004; Pal et al., 2004) and is involved in GATA1-dependent 
chromatin looping (Jing et al., 2008). FOG1 associates with the transcriptional repressors CtBP 
and NuRD (Fox et al., 1999; Hong et al., 2005), interactions thought to explain GATA1-dependent 
gene repression. However, although shown to be functionally important, NuRD is present at both 
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active and repressed genes (Miccio et al., 2010), leaving unresolved the exact mechanisms that 
determine the repressive activity of GATA1.  
 
TAL1/LMO2/Ldb1/E2A complex 
The TAL1 complex, composed of T-cell acute lymphocytic leukemia 1 (TAL1), LIM domain 
only 2 (LMO2), LIM domain-binding 1 (Ldb1), and E2A, interacts via LMO2 with the GATA1 NF 
(Osada et al., 1995; Wadman et al., 1997; Wilkinson-White et al., 2011). LMO2 likely functions as 
a scaffold that bridges the DNA-binding GATA1 and TAL1 proteins (Wadman et al., 1997; 
Wilkinson-White et al., 2011). The region of the GATA1 NF that contacts LMO2 has been defined 
structurally, and is distinct from the DNA- and FOG1-binding surfaces (Wilkinson-White et al., 
2011). TAL1, LMO2, and Ldb1 are all essential for erythrocyte and megakaryocyte differentiation 
(Hall et al., 2003; 2005; Li et al., 2010; Mikkola et al., 2003; Porcher et al., 1996; Yamada et al., 
1998). Unlike FOG1, association of the TAL1 complex with GATA1-regulated genes favors 
activated over repressed targets (Cheng et al., 2009; Kassouf et al., 2010; Soler et al., 2010; 
Tripic et al., 2009; Yu et al., 2009); however, like FOG1, the Ldb1 component of the complex 
promotes GATA1-mediated chromatin looping (Deng et al., 2012; Song et al., 2007). This 
complex has been shown to associate with several additional proteins such as the corepressor 
ETO-2 and the single-stranded DNA-binding protein SSBP2 (Goardon et al., 2006; Meier et al., 
2006; Schuh et al., 2005; Xu et al., 2007), which potentially modulate the activity of the complex.  
 
EKLF 
Erythroid Krüppel-like factor (EKLF) is an essential, erythroid-specific transcription factor that 
binds to the zinc finger domains of GATA1 (Merika and Orkin, 1995; Miller and Bieker, 1993; 
Nuez et al., 1995; Perkins et al., 1995; Southwood et al., 1996). EKLF and GATA1 co-occupy 
erythroid regulatory elements (Tallack et al., 2010), suggesting they cooperate to control red 
blood cell differentiation. Several developmental steps rely particularly upon EKLF, including 
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lineage commitment at the MEP stage, the developmental switch between fetal and adult 
hemoglobin expression, and cell cycle exit during terminal maturation (Frontelo et al., 2007; Pilon 
et al., 2008; Siatecka and Bieker, 2011; Zhou et al., 2010). 
 
Fli1 
Friend leukemia integration 1 (Fli1) is a transcription factor that binds to GATA1 via the zinc 
finger domains and plays a critical role in megakaryocyte development (Eisbacher et al., 2003; 
Hart et al., 2000; Kawada et al., 2001). The regulatory elements of many megakaryocyte-specific 
genes contain occupied, tandem binding sites for GATA1 and Fli1 (Lemarchandel et al., 1993; 
Tijssen et al., 2011; Wang et al., 2002), suggesting a functional interaction between the two 
factors. Importantly, Fli1 actively inhibits erythroid differentiation (Athanasiou et al., 2000). Current 
models suggest that Fli1 and EKLF (see above) play antagonizing roles in MEP lineage choice. 
While Fli1 represses erythropoiesis and promotes megakaryopoiesis, EKLF acts to promote 
erythroid development and inhibit the megakaryocytic program (Siatecka and Bieker, 2011).  
 
Gfi-1b 
Growth factor independent 1b (Gfi-1b) is a hematopoietic transcription factor essential for 
megakaryocyte and erythroid development (Saleque et al., 2002). It binds to the CF of GATA1 
(Huang et al., 2005; Rodriguez et al., 2005) and typically acts to repress gene expression 
(Grimes et al., 1996). Gfi-1b is thought to function in regulating cell proliferation during terminal 
maturation (Duan and Horwitz, 2003). 
 
PU.1 
PU.1, a hematopoietic transcription factor essential for the development of the monocytic, 
granulocytic, and lymphoid lineages, binds to the GATA1 CF (Hromas et al., 1993; McKercher et 
al., 1996; Nerlov et al., 2000; Rekhtman et al., 1999; Scott et al., 1994; Zhang et al., 1999). In 
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multipotent common myeloid progenitors, PU.1 and GATA1 are expressed together and act in 
opposition to balance lineage commitment decisions. Their physical interaction is mutually 
antagonistic, with GATA1 inhibiting PU.1 by preventing its interaction with the essential cofactor 
c-Jun (Zhang et al., 1999), and PU.1 blocking GATA1 function by inhibiting its ability to bind DNA 
(Zhang et al., 2000) and/or by recruiting a repressive complex (Rekhtman et al., 2003; Stopka et 
al., 2005). Downregulation of PU.1 expression is one of the first events associated with the 
restriction of differentiation to erythroid and megakaryocyte lineages (Nutt et al., 2005). 
 
CBP/p300 
The ubiquitously expressed lysine acetyltransferases CREB-binding protein (CBP) and p300 
bind to the GATA1 CF and augment transcriptional activity by increasing histone acetylation at 
GATA1 target genes (Blobel et al., 1998; Forsberg et al., 2000; Letting et al., 2003). In addition to 
modifying histone proteins, CBP/p300 acetylate GATA1 itself at two lysine-rich regions C-terminal 
to each zinc finger domain (Boyes et al., 1998; Hung et al., 1999). This acetylation is required for 
GATA1 chromatin occupancy and therefore erythroid maturation (Hung et al., 1999; Lamonica et 
al., 2006). 
 
Brd3 
Bromodomain-containing protein 3 (Brd3) is a ubiquitously expressed factor that binds to 
acetylated GATA1 and, through this interaction, is recruited to both activated and repressed 
GATA1 target genes (Lamonica et al., 2011). Although the function of Brd3 at these genes is 
unclear, a stable Brd3-GATA1 interaction is crucial for GATA1’s association with chromatin and 
stimulation of erythroid differentiation (Lamonica et al., 2011). Notably, the related proteins Brd2 
and Brd4 remain bound to chromatin during mitosis and facilitate postmitotic transcription (Dey et 
al., 2000; 2003; 2009; Yang et al., 2008; Zhao et al., 2011), implicating them as conveyors of 
epigenetic information. Additionally, Brd4 interacts with several well-characterized transcriptional 
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regulators, including P-TEFb and Mediator (Jang et al., 2005; Rahman et al., 2011; Wu and 
Chiang, 2007; Yang et al., 2005). Whether the same is true for Brd3 has yet to be established.  
 
RUNX1 
Runt-related transcription factor 1 (RUNX1) is a hematopoietic/vasculogenic-specific protein 
that binds to both the NAD and CAD of GATA1 (Elagib et al., 2003). RUNX1 first came to light 
because of its involvement in leukemic chromosomal translocations (Nucifora and Rowley, 1995), 
but it also plays a role in normal megakaryopoiesis (Heller et al., 2005; Ichikawa et al., 2004; 
Michaud et al., 2002; Song et al., 1999). GATA1 and RUNX1 cooperate to activate 
megakaryocyte genes in vitro (Elagib et al., 2003) and co-occupy megakaryocyte regulatory 
elements in vivo (Tijssen et al., 2011), but little else is known about how they function together to 
promote megakaryocyte maturation. 
 
RB 
The ubiquitously expressed tumor suppressor protein retinoblastoma (RB) binds to the 
GATA1 NAD (Kadri et al., 2009). Mice deficient for RB are nonviable and show erythroid defects 
(Jacks et al., 1992; Lee et al., 1992). In vitro systems have further demonstrated a role for RB in 
erythroid cell cycle exit and terminal differentiation (Clark et al., 2004). This suggests the GATA1 
NAD may regulate the capacity of GATA1 to control red blood cell survival and/or proliferation via 
RB binding. A truncated version of GATA1 lacking the NAD is aberrantly expressed in several 
hematopoietic disorders (discussed below). Whether loss of the GATA1-RB interaction is 
important for these phenotypes is so far unexplored. 
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Human pathophysiologies caused by GATA1 mutations 
Given the essential role of GATA1 in erythroid and megakaryocyte development, it is not 
surprising that defects in GATA1 cause human hematologic disorders. The first patients with a 
mutation in the GATA1 gene were described in 2000 (Nichols et al., 2000), and more reports of 
disease-associated GATA1 mutations followed. These genetic alterations can be transmitted 
through the germline or acquired somatically, and they result in various clinical phenotypes. 
Germline GATA1 mutations are found in the NF, at the exon 2 splice site, and in the stop 
codon. Because the GATA1 gene is located on the X chromosome (Zon et al., 1990), disorders 
caused by these mutations predominantly affect males. The seven reported NF mutations are of 
the missense variety and produce distinct forms of anemia and thrombocytopenia despite being 
similarly located within the GATA1 protein. Notably, clinical severity depends on the site and type 
of amino acid substitution, and different substitutions at the same position lead to disparate 
phenotypes. The mechanisms underlying this variation are not fully understood, although 
disrupted cofactor binding has been implicated (Ciovacco et al., 2008). Non-synonymous 
substitutions or deletions in the splice site of exon 2 impair production of full-length GATA1 and 
cause anemia in affected individuals (Hollanda et al., 2006; Sankaran et al., 2012). How the 
truncated form of GATA1 (called GATA1s or GATA1 short) acts at the molecular level to produce 
an erythroid-specific defect is unclear. Finally, a missense mutation in the stop codon predicted to 
result in the expression of an elongated GATA1 protein leads to a rare blood group phenotype 
(Singleton et al., 2013). Future studies of this naturally occurring mutation should illuminate the 
function of the poorly understood CAD.  
Acquired GATA1 mutations are found associated with almost all cases of transient 
myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL) in children with 
trisomy 21 (Down syndrome). Arising in utero, these alterations consist of insertions, deletions, 
splice site changes, nonsense mutations, and missense mutations within exon 2 that lead to the 
usage of a downstream start codon and production of the truncated GATA1 protein, GATA1s 
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(Malinge et al., 2009). Analogous germline GATA1 mutations found in anemic patients do not 
cause leukemia, underscoring the requirement for trisomy 21 (and likely secondary mutations) in 
these malignant diseases.   
 
The following work investigates molecular mechanisms that underlie several naturally 
occurring, disease-causing mutations in the hematopoietic transcription factor GATA1. Although 
many alterations in the GATA1 gene have been uncovered and their clinical phenotypes 
described, little is understood about how these mutations alter GATA1 function to cause 
hematologic disorders. By combining powerful gene complementation systems with structural, 
biochemical, and genomic approaches, we shed new light on pathways that lie at the core of the 
pathophysiology caused by GATA1 mutations.  
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Figure 1.1. Transcriptional regulation. 
General transcription factors (light green ovals and horseshoe) bind specific sequence motifs in 
the core promoter, including the B recognition element (BRE), the TATA box (TATA), the initiator 
element (Inr), and the downstream promoter element (DPE), and recruit RNA polymerase II 
(darker green blob) to the transcription start site (arrow). Tissue-specific transcription factors 
(various colors and shapes) bind regulatory elements (RE) in the proximal promoter and in distal 
enhancers and silencers where they interact with cofactors (red and blue ovals; pale mint 
diamond) to enhance or repress transcription. Distal elements influence promoters through 
physical contacts that involve looping of the DNA. These interactions take place on chromatin, 
where nucleosomes (grey) can be remodeled or modified (colored “lollipops”) to further influence 
the transcriptional state. The complex communications that occur among these transcriptional 
regulatory components allow for cell type specific control of gene expression. 
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Figure 1.2. Hematopoiesis. 
The anatomical sites and timing of hematopoiesis are depicted in the upper panel. The 
hematopoietic differentiation hierarchy is diagramed in the lower panel. HSCs are capable of 
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either self-renewal (curved arrow) or differentiation into mature blood lineages (straight arrows). 
Differentiation can occur via long described routes (thick arrows) and/or more recently described 
routes (thin arrows). AGM, aorta-gonad-mesonephros; dpc, days post conception; wpc, weeks 
post conception; HSC, hematopoietic stem cell; MPP, multipotent progenitor; LT, long-term 
repopulating; IT, intermediate-term repopulating; ST, short-term repopulating; LMPP, lymphoid-
primed MPP; ELP, early lymphoid progenitor; CLP, common lymphoid progenitor; CMP, common 
myeloid progenitor; GMP, granulocyte-macrophage progenitor; MEP, megakaryocyte-erythrocyte 
progenitor; CDP, common dendritic progenitor; MDP, monocyte-dendritic progenitor; NK, natural 
killer. Adapted from (Orkin and Zon, 2008) and (Rieger and Schroeder, 2012). 
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Figure 1.3. Transcription factor GATA1.  
The GATA1 gene is comprised of six exons, which are normally spliced together to produce 
GATA1 mRNA. The primary GATA1 open reading frame starts in exon 2, though an alternative 
downstream start codon is also present in exon 3. Depending on the initiation site utilized, 
translation of GATA1 mRNA will generate full-length GATA1 protein or a truncated version called 
GATA1s that lacks the N-terminal activation domain (NAD). When exon 2 splicing is disrupted (as 
is seen in human diseases caused by GATA1 mutations), abnormal production of only GATA1s 
mRNA and GATA1s protein follow. Similarly, disease-causing mutations in exon 2 that disrupt 
normal translation of the GATA1 mRNA lead to exclusive use of the downstream start codon and 
aberrant production of GATA1s protein. NF, N-terminal zinc finger; CF, C-terminal zinc finger; 
CAD, C-terminal activation domain. 
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CHAPTER 2. EXPERIMENTAL METHODS 
 
Constructs 
The murine GATA1 coding sequence alone or fused to the ligand-binding domain of the estrogen 
receptor was cloned into the MSCV-based retroviral vector MIGR1 to generate MIGR1-GATA1 
and MIGR1-GATA1-ER. Point mutations V205M, G208S, G208R, R216Q, R216W, D218G, 
D218Y, R202Q, or R217M were introduced by site-directed mutagenesis (QuickChange, 
Stratagene). Full-length GATA1 and the GATA1s (GATA1 Δ1-83) mutant were amplified by PCR 
with a single HA tag (YPYDVPDYA) at the N-terminus and inserted into MIGR1 to generate 
MIGR1-HA-GATA1 and MIGR1-HA-GATA1s. Murine FOG1 was cloned into MIGR1 with a single 
FLAG tag (DYKDDDK) fused to the C-terminus to generate MIGR1-FOG1-FLAG. The GATA1 
NF, GATA1(200-248), was amplified by PCR and inserted into pGEX-2T to generate pGEX-2T-
GATA1(200-248). Point mutations V205M, G208S, G208R, R216Q, R216W, D218G, or D218Y 
were introduced by site-directed mutagenesis (QuickChange, Stratagene). 
 
Cell culture 
G1E cells were cultured as described (Weiss et al., 1997). G1E cells were maintained in Iscove’s 
Modified Dulbecco’s Medium supplemented with 15% fetal bovine serum (FBS), 2% penicillin-
streptomycin, 0.6% kit-ligand (KL) conditioned medium (CM), 4.5 x 10-5 M monothioglycerol, and 
2 U/mL EPO.  KL CM was prepared from Chinese hamster ovary cells engineered to express 
murine KL (Genetics Institute, Cambridge, MA). Based on comparison with recombinant KL, 
approximately 50 ng/mL KL CM was used. Where indicated, G1E cells were treated with 100 nM 
E2 for 24-72 hours. G1ME cells were cultured as described (Stachura et al., 2006). G1ME cells 
were maintained in Minimum Essential Medium Alpha supplemented with 20% FBS, 1% 
penicillin-streptomycin, 1% glutamine, and 1% thrombopoietin (TPO) CM. TPO CM was prepared 
from cells engineered to express murine TPO (Villeval et al., 1997). Based on comparison with 
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recombinant TPO, approximately 20 ng/uL TPO CM was used. Murine erythroleukemia (MEL) 
and HEK-293 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% FBS, 2% penicillin-streptomycin, 1% glutamine, and 1% sodium pyruvate. Plat-E cells 
were cultured in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, 1% glutamine, 
1% sodium pyruvate, 1 µg/mL puromycin, and 10 µg/mL blasticidin. 
 
Retroviral infections 
Retroviral infections were carried out as described (Chou et al., 2009; Tripic et al., 2009). The 
MSCV-based retroviral vector MIGR1 was used to express wild-type or mutant murine GATA1 in 
G1E or G1ME cells. Viral particles were generated by transient transfection of Plat-E retrovirus 
packaging cells (Morita et al., 2000) using Lipofectamine 2000 according to manufacturer’s 
instructions, and viral supernatant collected 48 hours after transfection. For retroviral 
transduction, 1-4 mL of retroviral supernatant was mixed with 2-4 x 106 cells in the presence of 8 
µg/mL polybrene and 10 mM HEPES in 1 well of a 6-well plate and spun at 3200 rpm for 90 
minutes at room temperature. Cells were incubated at 37 °C for 3 hours and then resuspended in 
5 mL fresh media. EPO (2 U/mL) was added to the G1ME transductions to support 
erythromegakaryocytic differentiation.  
 
Western blotting 
Nuclear extracts were prepared according to standard methods (Dignam et al., 1983). In brief, 
cells were resuspended in ice-cold hypotonic buffer A and allowed to swell on ice for 30 minutes. 
After centrifugation, the nuclear pellet was resuspended in ice-cold high salt buffer C and 
incubated on ice for 30 minutes. After centrifugation at 13,000 rpm for 5 minutes supernatant 
fractions containing nuclear proteins were collected. Samples were fractionated through 
polyacrylamide gels and transferred onto nitrocellulose (Bio-Rad) or Immobilon-FL PVDF 
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(Millipore) membranes. Blots were probed with antibodies against GATA1 (sc-265; Santa Cruz), 
FOG1 (sc-9361; Santa Cruz), HA (sc-805; Santa Cruz), or β-actin (A3854, Sigma-Aldrich). 
Signals were detected with autoradiography using chemiluminescence (Thermo Scientific) by 
addition of horseradish peroxidase-conjugated anti-rat (A5795; Sigma-Aldrich) or anti-rabbit 
(1858415; Pierce) antibody, or with an Odyssey Imager after addition of infrared fluorescent-
labeled anti-rat (926-68029 or 926-32219; LiCor) or anti-goat (926-68024 or 926-32214; LiCor) 
antibody. Band intensities were quantified using ImageJ. 
 
Morphologic analysis 
For morphologic analysis, cells were centrifuged onto a glass slide and stained with May-
Grünwald-Giemsa (MGG) (Sigma-Aldrich), benzidine for hemoglobin (Orkin et al., 1975), or 
acetylcholinesterase (AChE), a rodent megakaryocyte marker (Jackson, 1973). Light microscopy 
images were acquired with a Zeiss Axioskop 2 microscope, Zeiss Axiocam camera, and Zeiss 
AxioVision 4.8 software (Carl Zeiss Microimaging) at room temperature.  
 
Hemoglobin quantification 
For hemoglobin assay, 5-10 x 106 cells were lysed in 100 µL of Drabkin’s reagent (D5941; Sigma-
Aldrich) and hemoglobin content was quantified by spectrophotometric measurement of 
absorbance at 540 nm on a SpectraMax 190 microplate reader. Hemoglobin content was 
normalized to total protein, which was determined via Bradford assay. 
 
Reverse transcription-quantitative polymerase chain reaction 
RNA was extracted with TRIzol (Invitrogen) from 0.1-5 x 106 cells and purified by phenol-
chloroform phase separation or with RNeasy Mini columns (Qiagen). Reverse transcription 
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reactions were performed using Superscript II (Invitrogen) or iScript (BioRad). Results were 
quantified using SYBR Green dye (Applied Biosystems) on an ABI Prism 7900HT or ViiA 7. Data 
were normalized to β-actin or Gapdh, both producing similar results. See below for primer 
sequences. 
 
Protein production and purification 
Construction, expression and purification of LMO2LIM2-Ldb1LID, dFOG1-F1, and the GATA1 NF 
have been previously described (Liew et al., 2000; Ryan et al., 2006; Wilkinson-White et al., 
2011). GATA1 NF mutants were expressed and purified using the same strategy as wild-type 
GATA1, with one-dimensional 1H nuclear magnetic resonance (NMR) spectroscopy used to 
confirm protein folding. 
 
Flow cytometry 
Flow cytometry was performed using FACSCanto or LSRFortessa flow cytometers (BD 
Biosciences) and data analyzed with BD FACSDiva software (BD Biosciences) or FlowJo 
software (TreeStar). Fluorescence-activated cell sorting (FACS) was performed with a FACSDiva 
or FACSAria II (BD Biosciences). For G1ME lineage analysis, cells were stained in phosphate 
buffered saline (PBS) with 2% FBS at room temperature for 30 minutes with the following 
antibodies: anti-Ter119-APC, anti-CD41-PE (BD Biosciences), and anti-CD42-PE (Emfret 
Analytics).  
 
Transfections and co-immunoprecipitations 
Transient transfections of HEK-293 cells were performed using polyethylenimine (PEI) at a ratio 
of PEI to DNA of 3:1. Cells were harvested 48 hours after transfection and nuclear extracts 
27 
 
prepared as described above. Immunoprecipitation (IP) was performed with anti-FLAG beads 
(Sigma-Aldrich). After extensive washing, elution was carried out with 3X FLAG peptide (Sigma-
Aldrich) and bound proteins analyzed by western blotting.  
 
Isothermal titration calorimetry 
Experiments were performed using a VP-ITC microcalorimeter (MicroCal) at 20 °C in 10 mM 
sodium phosphate, 10 mM NaCl, 1 mM DTT pH 7.5. For FOG1/GATA1 NF titrations, dFOG1-F1 
(200 µM) was titrated into a solution containing GATA1 (19 µM), G208S (20 µM), G208R (18 µM), 
R216W (18 µM), or D218Y (19 µM) (Liew et al., 2005). For GATA1 NF/DNA titrations, GATA1 
(189 µM), G208R (196 µM), R216W (187 µM), or D218Y (215 µM) were titrated into a solution 
containing a double-stranded 16 base pair oligonucleotide containing a GATC site (19-30 µM) 
(Liew et al., 2005). Data were analyzed using Origin 5.0 (MicroCal).   
 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed as described (Letting et al., 2003). Protein-
DNA crosslinking was performed by incubating cells in PBS with formaldehyde at a final 
concentration of 1% for 10 minutes at room temperature with gentle agitation. For anti-FOG1 
ChIP, cells were crosslinked in 1.5 mM EGS for 20 minutes at room temperature before 
formaldehyde treatment (Zeng et al., 2006). Glycine (0.125 M) was added to quench the reaction. 
Cells were then collected by centrifugation at 2000 rpm for 10 minutes and washed in PBS. 
Nuclei were isolated by incubation in cell lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl, 0.2% 
Nonidet P-40) for 10 minutes on ice followed by centrifugation at 2500 rpm for 5 minutes. Nuclei 
were lysed in nuclei lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) and the lysate 
sonicated with a Misonix Sonicator 3000 or a Bioruptor (Diagenode) to reduce the chromatin 
fragments to an average size of less than 500 base pairs. Soluble chromatin was diluted with IP 
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dilution buffer (20 mM Tris pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.01% SDS) 
and precleared by addition of 50 µg preimmune IgG and 50 µL Protein A/G Sepharose. An aliquot 
of precleared chromatin was set aside (input), and the remainder of the chromatin incubated with 
5-10 µg of antibody or preimmune IgG prebound to Protein A/G Sepharose. Protein A/G 
Sepharose pellets were washed once with IP wash buffer 1 (20 mM Tris pH 8.0, 2 mM EDTA, 50 
mM NaCl, 1% Triton X-100, 0.1% SDS), twice with high salt buffer (20 mM Tris pH 8.0, 2 mM 
EDTA, 500 mM NaCl, 1% Triton X-100, 0.01% SDS), once with IP wash buffer 2 (10 mM Tris pH 
8.0, 1 mM EDTA, 0.25 M LiCl, 1% Nonidet P-40, 1% sodium deoxycholate), and twice with TE 
(10 mM Tris pH 8.0, 1 mM EDTA). Immune complexes were eluted twice with 100 µL of IP elution 
buffer (0.1 M NaHCO3, 1% SDS). RNaseA (0.02 mg/mL), NaCl (0.3 M), and Proteinase K (0.06 
mg/mL) were added and crosslinks reversed by incubation at 65 °C overnight. DNA was purified 
by phenol-chloroform extraction followed by ethanol precipitation. Purified DNA was resuspended 
in 60 µL (immunoprecipitated DNA) or 133.4 µL (input DNA) water. DNA was quantified by real-
time quantitative PCR with SYBR Green dye (Applied Biosystems) on an ABI Prism 7900HT or 
ViiA7. Results were normalized to an input standard curve dilution series to correct for any 
differences in starting cell number or primer amplification efficiency. Antibodies used for IP were 
GATA1 (sc-265; Santa Cruz), FOG1 (sc-9361; Santa Cruz), LMO2 (AF2726; R&D Systems), 
TAL1 (sc-12984; Santa Cruz), and HA (sc-805; Santa Cruz). See below for primer sequences. 
 
Nuclear magnetic resonance spectroscopy 
Chemical shift perturbation experiments were carried out using 15N-LMO2LIM2-Ldb1LID (200 µM) in 
20 mM Mes, 100 mM NaCl, 1 mM DTT pH 6.5. Increasing amounts of unlabelled GATA1 NF 
(wild-type or mutant) were added up to one molar equivalent, with 1H,15N HSQC spectra recorded 
after each addition. The weighted average chemical shift changes for the peaks E118, G132, and 
V131 were calculated using the equation Δavg = (((δH)2 + (δN x 0.154)2)/2)1/2 (Ayed et al., 2001). 
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Gene expression profiling 
TRIzol (Invitrogen) extracted RNA was purified with RNeasy Mini columns (Qiagen). Hybridization 
(GeneChip Mouse Gene 1.0 ST Array; Affymetrix) and data analysis were performed at the 
University of Pennsylvania Microarray Core Facility. Data were imported into the Partek 
Genomics Suite (version 6.6; Partek, Inc.) and normalized using RMA to yield log2-transformed 
expression intensities for all transcript clusters on the array. After excluding control probe sets, 
principal components analysis and hierarchical clustering were performed to assess sample 
relatedness and contrast the global variation between and within replicate groups. One-way 
analysis of variance across the five conditions (each with three replicates) and all ten possible 
pairwise comparisons was performed, yielding a P value and fold change for all genes. P values 
were corrected for false discovery rate by the method of Benjamini and Hochberg (Benjamini and 
Hochberg, 1995). Genes with fold change ≥1.5 and P <0.05 were considered differentially 
expressed. Additionally, Gene Ontology analysis using Database for Annotation, Visualization, 
and Integrated Discovery (Dennis et al., 2003) was performed on select gene lists and Gene Set 
Enrichment Analysis (Mootha et al., 2003; Subramanian et al., 2005) was performed on whole 
datasets. Microarray data are deposited at Gene Expression Omnibus under accession number 
GSE43356.  
 
Primers 
Mutagenesis primers (5’ to 3’) 
 
GATA1_V205M 
Forward   GGCCAGAGAGTGTATGAACTGTGGAGCAACG 
Reverse   CGTTGCTCCACAGTTCATACACTCTCTGGCC 
 
GATA1_G208S 
Forward   GAGAGTGTGTGAACTGTTCAGCAACGGCTACTCC 
Reverse   GGAGTAGCCGTTGCTGAACAGTTCACACACTCTC 
 
GATA1_G208R 
Forward   GAGAGTGTGTGAACTGTAGAGCAACGGCTACTCC 
Reverse   GGAGTAGCCGTTGCTCTACAGTTCACACACTCTC 
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GATA1_R216Q 
Forward   GGCTACTCCACTGTGGCAGAGGGACAGGACAGG 
Reverse   CCTGTCCTGTCCCTCTGCCACAGTGGAGTAGCC 
 
GATA1_R216W 
Forward   GGCTACTCCACTGTGGTGGAGGGACAGGACAGG 
Reverse   CCTGTCCTGTCCCTCCACCACAGTGGAGTAGCC 
 
GATA1_D218G 
Forward   CCACTGTGGCGGAGGGGCAGGACAGGTCACTACC 
Reverse   GGTAGTGACCTGTCCTGCCCCTCCGCCACAGTGG 
 
GATA1_D218Y 
Forward   CCACTGTGGCGGAGGTACAGGACAGGTCACTACC 
Reverse   GGTAGTGACCTGTCCTGTACCTCCGCCACAGTGG 
 
GATA1_R202Q 
Forward   GCCCCTTGTGAGGCCCAAGAGTGTGTGAACTGTGG 
Reverse   CCACAGTTCACACACTCTTGGGCCTCACAAGGGGC 
 
GATA1_R217M 
Forward   ACTCCACTGTGGCGGATGGACAGGACAGGTCACTACC 
Reverse   GGTAGTGACCTGTCCTGTCCATCCGCCACAGTGGAGT 
 
 
Transcript qPCR primers (5’ to 3’) 
 
Alad 
Forward   ACTTTCACCCACTGCTTCGGA 
Reverse   CGATAGGCTGGACATCATCAGG 
 
Alas2 
Forward   TATGTGCAGGCCATCAACTACCCA 
Reverse   TTTCCATCATCTGAGGGCTGTGGT 
 
Alox5 
Forward   ACTACATCTACCTCAGCCTCATT 
Reverse   GGTGACATCGTAGGAGTCCAC 
 
Alox12 
Forward   CACACATGGTGAGGAAATGG 
Reverse   GATCACTGAAGTGGGGCTGT 
 
Casp3 
Forward   TGGCAACGGAATTCGAGTCCTTCT 
Reverse   TGAGCATGGACACAATACACGGGA 
 
Clec4d 
Forward   CGAGAGTAACGTGCATCCGA 
Reverse   AACAGGACAGCAGGTCCAAGTAC 
 
Cmtm7 
Forward   GTGCGACCTGATAATGATCCTC 
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Reverse   GGTGAGCACACGGTAGAAGC 
 
Cpox 
Forward   ATGCAATTTGAAGCCAGTCCGTGG 
Reverse   TCCCTTTGTAGAATAGCCTGGCCT 
 
Eraf 
Forward   GCCATGACAGAATTCCAGCAA 
Reverse   TTTGGACTTCAGAAAGGTCCTGTAT 
 
Fech 
Forward   AGAGAAGCGAGGTGGTCATTCTGT 
Reverse   ATGACTTTGTGGACAGTGGCTCCT 
 
Fyb 
Forward   CGAAGTTCAACACGGGGAGTA 
Reverse   TGTATTCCAGAAGGCGAGCTT 
 
Gata2 
Forward   CACCCCTAAGCAGAGAAGCAA 
Reverse   TGGCACCACAGTTGACACACT 
 
Gcnt2 
Forward   CTACGCGGGAAAGTTTTCGC 
Reverse   GTAGAGGTTGGGCAGGCTTA 
 
Gp1ba 
Forward   CTTGTTGCCAACGACCAAGCTGAA 
Reverse   AAGCCCTTTGGTATTGTGCGAAGC 
 
Gp6 
Forward   GTCTCTCCCAAGTGACCAGCTT 
Reverse   GAGCTGAGAGTGAGGGTTTAGCA 
 
Gypa 
Forward   TCACACGGCCCCTACTGAAGTGT  
Reverse   TCCCTGCCATCACGCGGAAAAT 
 
Hba-a1 
Forward   GTGGATCCCGTCAACTTCAAG 
Reverse   CAAGGTCACCAGCAGGCAGT 
 
Hbb-b1 
Forward   AACGATGGCCTGAATCACTTG 
Reverse   AGCCTGAAGTTCTCAGGATCC 
 
Hmbs 
Forward   ATTCCAAGAGGAGCCCAGCTAG 
Reverse   CATCATTAAGCTGCCGTGCA 
 
Kit 
Forward   AGCAGATCTCGGACAGCACC 
Reverse   TGCAGTTTGCCAAGTTGGAG 
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Klf1 
Forward   CACGCACACGGGAGAGAAG 
Reverse   CGTCAGTTCGTCTGAGCGAG 
 
Lrrc39 
Forward   AAACACCATGAAGACGTGAAGCGG 
Reverse   TTCCATCTTCCCTGGTCACCTTCT 
 
Ly75 
Forward   CACGGACAACCTGCGAATGT 
Reverse   GTATTGGCTACGGCATATCCATC 
 
Myb 
Forward   TGACTTTCGACACATGGCTCCTCA 
Reverse   AATGCACTTGGTGCTGCTCTCAAC 
 
Ms4a2 
Forward   TGGTTGGTTTGATATGCCTTTGT 
Reverse   CACTGCACCCCAGAATGGATA 
 
Pf4 
Forward   TTCTGGGCCTGTTGTTTCTG 
Reverse   GATCTCCATCGCTTTCTTCG 
 
Ppox 
Forward   TGCTGTAGAATTCTGGCCTCCGAA 
Reverse   TCCATCCTGTCCGTGTGCAGATAA 
 
Reep6 
Forward   GAAACACCCTCACAGCAGCACAAA 
Reverse   TGCACACCTTGGAGGAGAGATGTT 
 
Rragd 
Forward   TTTGGGACTCTTTGCTGCCAGTTG 
Reverse   TCTTATTGCTCTGGCCTGGAGCTT 
 
Slc4a1 
Forward   TGGAGGCCTGATCCGTGATA 
Reverse   AGCGCATCGGTGATGTCA 
 
Thbs1 
Forward   TAGCTGAGGCGGATCAGCAAATCT 
Reverse   GGGAAGCCAAAGGAGTCCAAATCA 
 
Urod 
Forward   CCTACATTCGTGATGTGGCCA 
Reverse   GGCAAAATGTCCATCCTTAGCA 
 
Uros 
Forward   ATGGAACGCAGATTCGGAGA 
Reverse   TGACCTAATGGCCAGTGAACCT 
 
Vwf 
Forward   TCATCGCTCCAGCCACATTCCATA 
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Reverse   AGCCACGCTCACAGTGGTTATACA 
 
Zfpm1 
Forward   CCTTGCTACCGCAGTCATCA 
Reverse   ACCAGATCCCGCAGTCTTTG 
 
 
ChIP qPCR primers (5’ to 3’) 
 
Abcb10 -6 kb 
Forward   AGTCTCTATGCCCAGCTTCTTTGG 
Reverse   AAGACAACGAGAGGAACAGGCAGT 
 
Alad +4 kb 
Forward   ACTGTGCAGCCTTCCCTCAAGTAA  
Reverse   TAGCCACAAGATAAGCCAGTGCCA 
 
Alas2 +2 kb 
Forward   AGGGCAGGACTTTGCCTCTAATCT  
Reverse   AGATGTCCCAGTTCCTGCAGGTTT 
 
Capn2 +13 kb 
Forward   TAATGGGAGTTCCCAGCATTT 
Reverse   GCACAAGAGAGGATGACCTTAT 
 
Eraf prom 
Forward   TGCCTGCGTCTCGCTTAGT 
Reverse   GCTGAGCCCGCCTCATC 
 
Ermap +1.7 kb 
Forward   GGACAGATTCAGGAGGAGAGTA 
Reverse   CTTTGCACCTCTGAGCTATGAT 
 
Fli1 prom 
Forward   GCCCAGTTACATTCATGCAC 
Reverse   TGCAGACTTCAGGAATCAGG 
 
Gata2 -3.9 kb 
Forward   GAGATGAGCTAATCCCGCTGTA 
Reverse   AAGGCTGTATTTTTCCAGGCC 
 
Gp1ba prom 
Forward   TGGTGGCTAGTAGCTGCAAAGTC 
Reverse   TTATCAGCTCTCTGCACAGCATTC 
 
Gypa prom 
Forward   GCAGTTATGCAGACCTCTAGTT 
Reverse   CCTCTATCCGTTGACACACATT 
 
Hbb HS2 
Forward   GGGTGTGTGGCCAGATGTTT 
Reverse   CACCTTCCCTGTGGACTTCCT 
 
Hbb HS3 
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Forward   CTAGGGACTGAGAGAGGCTGCTT 
Reverse   ATGGGACCTCTGATAGACACATCT 
 
Hba-a1 -12 kb 
Forward   AACCCTGACTCAAAACAACAAAGTAA 
Reverse   GGTTTCTGAGTTTCCTTATCTGCAA 
 
Hbb-b1 prom 
Forward   CAGGGAGAAATATGCTTGTCATCA 
Reverse   GTGAGCAGATTGGCCCTTACC 
 
Il9r prom 
Forward   ACATTGCCGAGGACACAGTTCTCT 
Reverse   TGCATTGCGGAAGGTGAGTCTGTA 
 
Itga2b prom 
Forward   TCCTGCTCTTGAATGCTGTG 
Reverse   GGGAGGAAGTGGGTAAATGTC 
 
Kit +33 kb 
Forward   TGGCAGTCCTGGTTGTAGCA 
Reverse   GCTGCAAGCATGCGATCA 
 
Klf1 prom 
Forward   TCTGCTCAAGGAGGAACAGAGCTA 
Reverse   GGCTCCCTTTCAGGCATTATCAGA 
 
Lrrc39 prom 
Forward   TTCCCTGGTGTCTGTAGGAACACA 
Reverse   GGGCTTCTGTGCAAAGGTTCAACT 
 
Lyl1 prom 
Forward   TCAGCATTGCTTCTTATCAGCC 
Reverse   CGCAGAGGCCAGAGGATG 
 
Myh9 +5 kb 
Forward   CACGATTACGGTGACCTTTCTA 
Reverse   CTTGACTGTGCAGAAGGAAATG  
 
Pf4 prom 
Forward   GCTGCTGGCCTGCACTTAAG 
Reverse   GCCACTGGACCCAAAGATAAAG 
 
Pkhd1l1 +0.4 kb 
Forward   CCGTTCTTCTTGCTCTCCTTGTGT 
Reverse   AGCTTACCCTGGAAGTGACAGACA 
 
Rragd +4 kb 
Forward   CTTGGAATCCGAGGAAATGA 
Reverse   TGGATATCCTCTGGGGAGTG 
 
Slc4a1 +1.6 kb 
Forward   ATCAGAAGCAACCTAGAGTCCAGC 
Reverse   TAAGAGTGTAGGACCAGCAGGCAA 
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Slc4a1 prom 
Forward   CTGAGCAGTCAAGCCTTAGTTCAC 
Reverse   CCTGTCCAGTCCCTAAGGTCTTT 
 
Slc22a4 +1.2 kb 
Forward   CAGCAATGGTGGGAAGGCAGATTT 
Reverse   ACAAGCACTGTTTCTGGCAAGAGC 
 
Spna1 prom 
Forward   ATGCCTCACTTTGTCCTGAGCTGT 
Reverse   TGTCCCTCTGGGCCTTGTTTATCA 
 
Src +5 kb 
Forward   TTTCCTGTCCTGAAGTGGGTGGAA 
Reverse   TGGATGGCTACAGCCACCTTAACT 
 
Thbs1 -45 kb 
Forward   TCACGCTGTGTTGATGAGAGCAGA 
Reverse   ACTGGGTAGCAGTTCCAAGGGATT 
 
Tph1 prom 
Forward   ACACGCTTTCACAGAAACCACCAC 
Reverse   TCTCCCATTAACCGCGTTTCCTCT 
 
Tubb1 +3 kb 
Forward   CTGTGTTGACTTGAAGGCCTTTGG 
Reverse   TGACTCCTGTGGCACATAAGGGTA 
 
Uros +6 kb 
Forward   TACTGCCTGGAAAGGCAAGTGAGA 
Reverse   ATCTGCCACTGGTATGTCCCAGAA 
 
Uros +11 kb 
Forward   ACTGCCTTGGTGCTCGTGTGATAA 
Reverse   AGCTTGCAGAACTTAGCAGCTTCC 
 
Vwf -11 kb 
Forward   ATATCAGGCCTTTCCTCCAAGGGT 
Reverse   GCAACTGCCTGCCATGCTATCAAT 
 
Zfpm1 +2 kb 
Forward   CTTTTCTCCTGCCCAGTCG 
Reverse   TGCTGTTGCCTCGAACC 
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CHAPTER 3. MISSENSE MUTATIONS IN THE N-TERMINAL ZINC FINGER OF 
GATA1 IMPAIR BINDING TO ESSENTIAL COFACTORS 
 
 
 
Research presented in this chapter was carried out in collaboration with the laboratory of Joel 
Mackay and Jacqueline Matthews. Protein production and purification, isothermal titration 
calorimetry, and nuclear magnetic resonance spectroscopy were performed by Lorna Wilkinson-
White, a postdoctoral fellow in the Matthews lab.  
This work was originally published in Blood. Amy E. Campbell, Lorna Wilkinson-White, Joel P. 
Mackay, Jacqueline M. Matthews, and Gerd A. Blobel. Analysis of disease-causing GATA1 
mutations in murine gene complementation systems. Blood. 2013. 121(26):5218-5227. © The 
American Society of Hematology. 
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Introduction 
Erythrocyte and megakaryocyte development are under the control of the hematopoietic-specific 
transcription factor GATA1 (Fujiwara et al., 1996; Shivdasani et al., 1997). GATA1 promotes the 
differentiation of these lineages by activating all known erythroid- and megakaryocyte-specific 
genes and silencing genes associated with the immature, proliferative state and alternative 
lineages (Ferreira et al., 2005). 
GATA1 contains two highly conserved zinc finger domains (see Chapter 1), which function to 
regulate its transcriptional abilities. The CF binds to the canonical DNA sequence motif 
(A/T)GATA(A/G) while the NF stabilizes DNA interactions by contacting non-canonical GATC and 
palindromic ATC(A/T)GATA(A/G) motifs (Martin and Orkin, 1990; Newton et al., 2001; Trainor et 
al., 1996). The NF also binds coregulators, including the multi-zinc finger protein FOG1 (Tsang et 
al., 1997). Like GATA1, FOG1 is required for erythroid and megakaryocyte development, and 
disrupting the GATA1-FOG1 interaction impairs maturation of these lineages (Chang et al., 2002; 
Crispino et al., 1999; Tsang et al., 1998).  Activation and repression of most GATA1-regulated 
genes requires FOG1 (Johnson et al., 2007; Muntean and Crispino, 2005), as does silencing of 
mast cell-specific genes (Cantor et al., 2008; Chlon et al., 2012; Gregory et al., 2010). FOG1 also 
modulates GATA1 chromatin occupancy at a subset of genomic sites (Chlon et al., 2012; Letting 
et al., 2004; Pal et al., 2004). Additionally, the TAL1 complex, composed of TAL1, E2A, LMO2, 
and Ldb1, interacts via LMO2 with the GATA1 NF (Wadman et al., 1997; Wilkinson-White et al., 
2011). TAL1, LMO2, and Ldb1 are essential for erythrocyte and megakaryocyte differentiation (Li 
et al., 2010; Porcher et al., 1996; Yamada et al., 1998). TAL1 complex recruitment occurs 
predominantly at GATA1-activated genes and tends to be depleted at sites where GATA1 
functions as a repressor (Cheng et al., 2009; Tripic et al., 2009). The interaction surfaces of 
GATA1 that contact DNA, FOG1, and LMO2 have been defined previously (Liew et al., 2005; 
Omichinski et al., 1993; Wilkinson-White et al., 2011). 
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Missense mutations in the GATA1 NF cause distinct forms of congenital anemia and 
thrombocytopenia. Although similarly located, the seven reported mutations produce a wide 
spectrum of phenotypes (Balduini et al., 2004; Del Vecchio et al., 2005; Dührsen et al., 2011; 
Freson et al., 2001; 2002; Kratz et al., 2008; Mehaffey et al., 2001; Nichols et al., 2000; Phillips et 
al., 2007; Raskind et al., 2000; Tubman et al., 2007; Yu et al., 2002) (Table 3.1). Clinical severity 
depends on the site and type of substitution, and different substitutions at the same amino acid 
position produce disparate phenotypes. Broadly, the diseases fall into two categories: severe 
thrombocytopenia with pronounced anemia (V205M, G208R, D218Y) and moderate 
thrombocytopenia with minimal or no anemia (G208S, R216Q, R216W, D218G). There is also 
one case of congenial erythropoietic porphyria (CEP) associated with a R216W substitution. Five 
mutations lie on defined surfaces: R216Q and R216W sit on the DNA-binding face, while V205M, 
G208S, and G208R cluster on the FOG1-binding face (Figure 3.1). D218G and D218Y fall 
outside these surfaces but diminish FOG1 binding in GST-pulldown experiments (Freson et al., 
2001; 2002; 2003). Structural and in vitro studies categorized GATA1 NF mutations into two 
groups, affecting either DNA or FOG1 binding. However, this classification fails to fully explain the 
degree of phenotypic variation caused by mutations on the same interaction face. For example, 
both R216Q and R216W are thought to disrupt DNA binding but the latter causes erythroid 
porphyria while the former does not (Phillips et al., 2007; Yu et al., 2002). Similarly, it is unknown 
whether the disparate clinical phenotypes caused by different substitutions at residues G208 (Del 
Vecchio et al., 2005; Mehaffey et al., 2001) and D218 (Freson et al., 2001; 2002) simply disrupt 
interaction with FOG1 to different extents or affect GATA1 function in qualitatively different ways. 
Moreover, D218 falls outside the known FOG1-binding surface, raising the possibility that this 
residue might connect to other GATA1 cofactors. Understanding how GATA1 NF mutations 
produce human diseases will enhance our understanding of molecular hematopoiesis and refine 
clinical care by linking prognosis and potential therapies to patient genotypes. 
We examined mechanisms by which missense mutations in the NF alter GATA1 function 
using G1E and G1ME systems (see Chapter 1), which enable the study of GATA1 mutants in 
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their natural context at physiological expression levels. G1E cells are erythroid precursors that fail 
to mature owing to a lack of GATA1 (Weiss et al., 1997). Introducing a conditional form of GATA1 
(GATA1 fused to the ligand-binding domain of the estrogen receptor [GATA1-ER]) imparts E2-
dependent erythroid maturation in a manner largely reproducing that of wild-type cells (Pilon et 
al., 2011; Welch et al., 2004). G1ME cells are GATA1-null bipotential megakaryocyte-erythroid 
progenitors that undergo terminal differentiation toward the erythroid and megakaryocyte lineages 
when reconstituted with GATA1 and grown in the appropriate cytokine environment (Stachura et 
al., 2006). Using these cell-based systems, complemented by structural, biochemical, and 
transcriptome analyses, we comprehensively characterize the effect of NF missense mutations 
on GATA1 function, and uncover novel pathways underlying GATA1-mediated hematologic 
disorders. 
 
Results 
Erythroid defects caused by GATA1 NF mutations are recapitulated in an erythroid gene 
complementation system 
To determine the capacity of GATA1 NF mutants to promote erythroid maturation, wild-type 
or mutant GATA1-ER fusions were stably introduced into G1E cells. (From here on, GATA1-ER 
will be referred to simply as GATA1.) All proteins were expressed equivalently and at levels 
comparable to endogenous GATA1 (Figure 3.2). Upon E2 treatment, wild-type GATA1 induced 
erythroid maturation as evidenced by morphology and staining with the hemoglobin dye benzidine 
(Figure 3.3A). In contrast, the V205M, G208R, and D218Y versions of GATA1 were inactive, and 
G208S displayed only minimal residual activity (Figure 3.3A). The R216Q, R216W, and D218G 
mutations produced subtle deficiencies detectable upon hemoglobin quantification (Figure 3.3A 
and Figure 3.4). 
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GATA1-induced morphologic transitions were reflected in gene expression changes (Figure 
3.3B-E). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of 
erythroid GATA1 target genes after 24 hours of E2 treatment showed that the V205M, G208S, 
G208R, and D218Y mutations reduced transcriptional activation (Figure 3.3B,D) and repression 
(Figure 3.3C,E) to <20% of wild-type, while R216Q, R216W, and D218G caused less severe 
defects. Fundamentally similar gene expression patterns were observed at over 30 genes (Table 
3.2). Notably, G208R affected transcription more than its paired mutant G208S, and the R216Q 
and D218G mutations impaired activation more than repression. Gene expression changes were 
not simply a reflection of delayed maturation because they were also observed at 48 hours of E2 
treatment (Figure 3.5). Importantly, all mutant proteins properly regulated a subset of target 
genes, including Zfpm1 and Clec4d (Figure 3.3B,C), suggesting that missense mutations do not 
trigger a global misfolding of the NF. To examine this assumption more rigorously, we obtained 
one-dimensional 1H NMR spectra of all mutants for which such analyses had not yet been 
performed. They revealed substantial tertiary structure in all mutant NFs (Figure 3.6 and (Liew et 
al., 2005)), indicating that the functional consequences of GATA1 NF mutations are not due to 
global misfolding.  
Among GATA1 mutations, R216W is uniquely associated with CEP. Expression analysis of 
genes encoding heme biosynthetic enzymes revealed a >50% decrease in Alas2 and Uros levels 
in cells harboring the R216W mutation (Figure 3.7). Although reduced UROS activity (to <5% of 
wild-type levels) causes CEP, to what extent the observed transcriptional defect could account for 
this clinical phenotype remains unclear (Balwani and Desnick, 2012).  
In summary, the effects of GATA1 NF mutations on cellular morphology, hemoglobin 
concentrations, and gene expression profiles in G1E cells essentially mimic clinical erythroid 
phenotypes (see Table 3.6). These findings validate G1E cells as an appropriate and informative 
model system with which to study disease-causing GATA1 mutations. 
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Megakaryocyte defects caused by GATA1 NF mutations are recapitulated in a megakaryocyte-
erythroid gene complementation system 
To test GATA1 NF mutants in a megakaryocytic context, we expressed them in G1ME cells 
(GATA1-ER fusions are not functional in these cells) and cultured the cells with TPO and EPO to 
support erythromegakaryocytic differentiation. All proteins were expressed equivalently and at 
levels comparable to endogenous GATA1 (Figure 3.8). Wild-type GATA1 promoted 
megakaryocyte maturation, evidenced by large CD42-positive cells with multilobular nuclei that 
stained positive for acetylcholinesterase (Figure 3.9A and Figure 3.10). The V205M, G208S, 
G208R, and D218Y mutations caused a marked deficiency in megakaryocyte maturation, while 
R216Q, R216W, and D218G led to mild defects (Figure 3.9A and Figure 3.10). Importantly, the 
ability of GATA1 NF mutants to promote the erythroid maturation of G1ME cells was consistent 
with that observed in G1E cells (compare Figure 3.3 to Figure 3.10).  
Megakaryocytic GATA1 target gene expression was measured by RT-qPCR analysis of 
FACS-purified CD42-positive cells (Figure 3.9B-E). The V205M, G208S, G208R, and D218Y 
mutations reduced both activation (Figure 3.9B,D) and repression (Figure 3.9C,E) to <20% of that 
achieved by wild-type GATA1, while R216W had only a mild, gene-specific effect on activation. 
Although cells harboring the R216Q and D218G mutations displayed no gross morphological 
deficiencies, there were notable changes in transcriptional activities. Specifically, both mutants 
displayed a ~60% loss of activation but only a 40% reduction in repression (Figure 3.9D-E). 
These gene expression changes may explain the thrombocytopenia reported in these patients 
and suggest that defects caused by R216Q and D218G mutations manifest themselves at a later 
stage in megakaryocytic maturation or platelet production, which are not detected in this assay. 
The R216Q and D218G mutations affect transcription in megakaryocytes more strongly than in 
erythroid cells (compare Figure 3.3D-E to Figure 3.9D-E), suggesting differential sensitivities to 
diminished GATA1 function between the two cell lineages. This is consistent with the presentation 
of thrombocytopenia but minimal anemia in these patients. Essentially, the same patterns of 
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misregulation were seen at over 20 genes (Table 3.3). Importantly, all mutant proteins properly 
regulated a subset of target genes, including Reep6 and Gcnt2 (Figure 3.9B,C), indicating that no 
mutation completely abrogated GATA1 function in megakaryocytes.  
In summary, the ability of mutant GATA1 proteins to promote megakaryocyte maturation in 
G1ME cells as assessed by morphology, acetylcholinesterase staining, CD42 expression, and 
transcriptional profiles generally parallels the degree of thrombocytopenia seen in patients (see 
Table 3.6). In lieu of primary cells from patients, G1E and G1ME cells provide convenient, faithful, 
and robust systems in which to study GATA1 mutations. 
 
A subset of GATA1 NF mutations diminish FOG1 binding 
Except for V205M, studying the impact of GATA1 NF mutations on cofactor binding has been 
limited to in vitro protein association assays using select FOG1 zinc fingers but not the entire 
molecule (Freson et al., 2001; 2002; 2003; Mehaffey et al., 2001; Nichols et al., 2000; Yu et al., 
2002). We compared the binding of all GATA1 NF mutants to full-length FOG1 by co-
immunoprecipitation (co-IP) following expression in HEK-293 cells. The V205M, G208R, and 
D218Y mutations diminished FOG1 binding by ~70%, 80% and 50%, respectively, while G208S 
caused only a ~20% reduction (Figure 3.11). Proteins containing R216Q, R216W, or D218G 
mutations bound indistinguishably from wild-type GATA1 (Figure 3.11). Similar results were 
obtained when purified GATA1 NF proteins were examined by isothermal titration calorimetry 
(ITC) (Figure 3.12 and Table 3.4 and (Liew et al., 2005)). 
Because cofactor association is influenced by cellular context, we examined the ability of 
GATA1 NF mutants to recruit FOG1 to target genes in erythroid cells by ChIP. Importantly, the 
V205M mutation has been reported to diminish GATA1 chromatin occupancy at select sites 
(Chlon et al., 2012; Letting et al., 2004). We found that V205M, G208S, G208R, and D218Y 
reduced GATA1 binding at these sites while the remaining mutations were innocuous in this 
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regard (Figure 3.13A). To assay FOG1 association independently of GATA1 loading, we 
examined sites where GATA1 chromatin occupancy was FOG1-independent, including single and 
palindromic motifs near active and repressed genes (Figure 3.13B). Consistent with co-IP data, 
V205M, G208R, and D218Y severely diminished FOG1 recruitment, G208S had a mild impact, 
and R216Q, R216W, and D218G had little to no effect (Figure 3.13C-D). Similar observations 
were made at over 20 target sites (Table 3.5). Furthermore, as previously described (Cantor et 
al., 2008; Chlon et al., 2012; Gregory et al., 2010), mutations that diminish the GATA1-FOG1 
interaction caused aberrant activation of mast cell genes (Figure 3.14). 
Two results are especially notable. First, G208S and G208R differ in the degree to which they 
disrupt binding to FOG1, which mirrors the associated disease severity in patients and supports 
the notion that inhibition of FOG1 binding, and not another undefined GATA1 cofactor, accounts 
for the phenotype. Second, substitution of tyrosine for aspartic acid at position 218, which falls 
outside the known FOG1 interaction domain, inhibits FOG1 binding, while a glycine substitution at 
the same residue does not (see also below), implicating critical features in the mode of NF 
interactions that were not predicted by structural studies. In summary, disruption of FOG1 binding 
in vitro is matched by failure to recruit FOG1 in vivo. This diminishes GATA1 chromatin 
occupancy at select sites, affects both gene activation and repression, and generally produces 
the most pronounced defects in erythroid and megakaryocytic differentiation in cell-based assays 
and in patients. 
 
GATA1 harboring NF DNA-binding surface mutations occupies target genes normally 
Because R216 contacts DNA in structural studies (Omichinski et al., 1993), it has been 
proposed that R216Q and R216W cause disease by disrupting GATA1 DNA binding (Phillips et 
al., 2007; Yu et al., 2002). We measured by ITC the affinities of wild-type or mutant GATA1 NF 
proteins for a 16 base pair oligonucleotide containing a GATC site (Figure 3.15 and Table 3.4 and 
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(Liew et al., 2005)). NF proteins with V205M, G208S, G208R, D218G, or D218Y mutations bound 
DNA with similar affinities as wild-type. In contrast, the R216Q and R216W mutants showed no 
measurable binding to DNA. Based on these and previous data (Liew et al., 2005; Newton et al., 
2001; Yu et al., 2002), R216Q and R216W would be expected to disrupt GATA1 binding to 
palindromic and GATC motifs in vivo. Surprisingly, ChIP analysis revealed that GATA1 harboring 
R216Q or R216W mutations bound all examined target sites normally, including those containing 
palindromic motifs and regardless of whether strong or weaker GATA1 occupied sites were 
considered (Figure 3.13A-B and Figure 3.16A). In accordance with in vitro results, V205M, 
G208S, G208R, D218G, and D218Y mutants showed normal GATA1 chromatin occupancy at all 
sites except those at which association with FOG1 is required (Figure 3.13A-B and Figure 3.16B). 
Thus, in contrast to in vitro observations, mutations on the DNA-binding surface of the NF do not 
significantly impair GATA1 target site occupancy in vivo. Therefore, these mutations likely cause 
human disease through alternate mechanisms. 
 
R216Q and D218G mutations specifically diminish TAL1 complex binding resulting in overlapping 
gene expression signatures 
Since the R216Q, R216W, and D218G mutations do not measurably disrupt FOG1 
recruitment or DNA binding in vivo, we examined whether they affect association with LMO2, a 
member of the TAL1 complex, because it interacts directly with the GATA1 NF in a manner 
permitting simultaneous FOG1 binding (Wilkinson-White et al., 2011). Although no NF mutations 
affect residues known to bind LMO2, R216 and D218 flank R217, which contributes to the 
GATA1-LMO2 interaction (Wilkinson-White et al., 2011). ChIP analysis revealed that the R216Q 
and D218G mutations diminished LMO2 occupancy at GATA1 target genes (Figure 3.17A-B). 
This trend was more apparent when the LMO2 ChIP signals were normalized to those of GATA1 
(Figure 3.17C). In contrast, none of the remaining mutations impaired LMO2 recruitment (Figure 
3.17A-C). The same binding profiles were observed for TAL1 (Figure 3.17D), suggesting the 
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entire TAL1 complex is recruited less efficiently by the R216Q or D218G mutants. Similar 
occupancy profiles were observed at over 20 target sites (Table 3.5). These results were 
surprising given that R216Q falls on the DNA-binding surface and D218Y disrupts FOG1 binding. 
However, a shared molecular defect is consistent with the similar clinical phenotypes caused by 
R216Q and D218G mutations. Furthermore, a qualitative difference in TAL1 complex binding 
between R216Q and R216W, and between D218G and D218Y, might explain each pair’s 
divergent patient presentations. Notably, disruption of TAL1 complex binding by R216Q and 
D218G did not reduce GATA1 chromatin occupancy at any site (Figure 3.13A-B and Figure 3.16), 
suggesting that unlike FOG1, association with the TAL1 complex is not required for stable binding 
of GATA1 to its target genes. Additionally, disruption of TAL1 complex recruitment impinges on 
gene activation more so than on repression (Figure 3.3D-E, Figure 3.9D-E, and Figure 3.14), 
consistent with previous reports of this cofactor predominantly occupying GATA1-activated genes 
(Cheng et al., 2009; Kassouf et al., 2010; Soler et al., 2010; Tripic et al., 2009; Yu et al., 2009).  
Due to the low affinity of the GATA1-LMO2 interaction (Wilkinson-White et al., 2011), co-IP 
was unreliable for comparing the binding of GATA1 NF mutants to LMO2 (data not shown). 
Therefore, we turned to two-dimensional 1H,15N NMR spectroscopy. The addition of purified 
GATA1 NF protein containing a R216W or D218Y mutation to a preformed LMO2-Ldb1 complex 
caused peak shifts similar to those induced by wild-type protein, indicating that these mutations 
did not affect the interaction between the GATA1 NF and LMO2 (Figure 3.18 and data not 
shown). Titration of D218G induced chemical shift changes that were smaller in magnitude than 
those induced by wild-type protein, consistent with a reduction in LMO2 binding affinity (Figure 
3.18). However, the signals were qualitatively similar and shifted in the same directions, indicating 
that the nature of the interaction was fundamentally unaltered compared to wild-type. Addition of 
R216Q did not result in significant shifts to any peaks in the spectrum, demonstrating that this 
mutation markedly impairs LMO2 binding (Figure 3.18). Together, these data support our in vivo 
results showing that R216Q and D218G inhibit recruitment of LMO2 to GATA1 bound genes.  
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To strengthen our finding that the R216Q and D218G mutations affect LMO2 binding, we 
compared them to two GATA1 substitutions (R202Q and R217M) previously shown to diminish 
LMO2 binding in vitro (Wilkinson-White et al., 2011). In G1E cells, GATA1 harboring R202Q or 
R217M induced erythroid maturation and transcriptional activities almost perfectly matching the 
R216Q and D218G mutants (Figure 3.19A-D, compare to Figure 3.3 and Figure 3.4). ChIP 
confirmed that R202Q and R217M impaired recruitment of LMO2 but not FOG1 (Figure 3.19E-F). 
This strongly supports the idea that TAL1 complex disruption by R216Q and D218G mutations 
accounts for their disease-causing effects, implicating for the first time the TAL1 complex in the 
pathogenesis of disorders caused by GATA1 mutations.  
To obtain a broad and unbiased comparison of wild-type GATA1 and paired mutants that 
affect TAL1 complex binding (R216Q and D218G) and those that do not (R216W and D218Y), we 
examined transcriptomes by microarray. Hierarchical clustering analysis revealed that R216Q 
and D218G were highly similar (Figure 3.20A). Notably, there was substantial overlap among 
genes affected at least twofold by the R216Q and D218G mutations that exceeded the R216Q 
and R216W overlap (Figure 3.20B). Similar results were observed when a 1.5-fold cut-off was 
used. ChIP confirmed diminished LMO2 occupancy at genes downregulated by the R216Q and 
D218G mutations (Figure 3.20C-D). Thus, gene profiling cemented a shared mechanism of action 
for the R216Q and D218G mutations, namely disruption of TAL1 complex interaction.  
Global expression changes induced by GATA1 harboring R216W are most similar to those of 
wild-type (Figure 3.20A), suggesting that alterations caused by this mutation are subtle. We note 
that genes severely misregulated by R216W mutation show no defect in GATA1 occupancy 
(Figure 3.21), further supporting the conclusion that the R216W mutation impairs functions other 
than DNA binding. 
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Figure 3.1. Locations of GATA1 NF mutations. 
Space filling model of the GATA1 NF from PDB code 1Y0J with DNA binding residues in red 
(based on PDB ID code 1GAT), FOG1 binding residues in cyan, and LMO2 interacting residues 
in blue. The locations of disease-associated mutations are noted. The middle structure has been 
rotated 120 degrees around a horizontal axis from the leftmost model, and the rightmost structure 
is rotated a further 80 degrees. 
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Figure 3.2. Expression of GATA1 NF mutants in G1E cells. 
Anti-GATA1 and, as a loading control, anti-β-actin western blots of extracts from G1E cells 
expressing indicated versions of GATA1 after 24 hours of E2 treatment. Wild-type and mutant 
proteins were expressed equally (A) at levels similar to endogenous GATA1 in MEL cells (B). 
Bands were quantified by densitometry and relative GATA1 levels are noted below each panel. 
ND = not determined. The black vertical line in (B) demarcates an unrelated excised lane. 
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Figure 3.3. GATA1 NF mutations impair erythroid differentiation.  
(A) MGG and benzidine staining of G1E cells expressing wild-type or mutant GATA1 after 72 
hours of E2 treatment. The percentage of hemoglobin-positive cells is indicated in the upper right 
corner of each benzidine panel. Scale bars, 20 µm (left panels) and 50 µm (right panels). (B-C) 
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Expression of GATA1-activated (B) and GATA1-repressed (C) genes after 24 hours of E2 
treatment as determined by RT-qPCR, normalized to β-actin, and plotted as fold change from 
uninfected samples. (D-E) Average transcriptional profiles after 24 hours of E2 treatment for all 
activated (D, n = 24) and repressed (E, n = 6) genes examined. Note that the reduction in 
transcriptional repression by R216Q and D218G is not statistically significant. * P <0.05. Error 
bars denote SEM (n = 3) unless otherwise noted.  
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Figure 3.4. Hemoglobin quantification in G1E cells expressing GATA1 NF mutants. 
Hemoglobin concentrations of indicated cells analyzed after 72 hours of E2 treatment. 
Representative images of cell pellets are shown above. Error bars denote SEM (n = 3). 
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Figure 3.5. Impaired transcription in GATA1 NF mutants is not due to delayed maturation. 
Expression of GATA1-activated (A) and GATA1-repressed (B) genes after 24 hours and 48 hours 
of E2 treatment as determined by RT-qPCR, normalized to β-actin, and plotted as fold change 
from uninfected samples. Error bars denote SEM (n = 3).  
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Figure 3.6. GATA1 proteins harboring NF mutations are structured. 
One-dimensional 1H NMR spectra of indicated GATA1 NF proteins showing a well-defined tertiary 
fold. 
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Figure 3.7. Effect of GATA1 NF mutations on genes encoding heme biosynthetic proteins. 
(A) Expression of all eight heme biosynthetic enzymes in G1E cells expressing indicated GATA1 
versions after 24 hours and 48 hours of E2 treatment as determined by RT-qPCR, normalized to 
β-actin, and plotted as fold change from uninfected samples. (B) Results from (A) at 24 hours 
were plotted as fold change from GATA1-expressing cells. (C) Expression of additional genes 
implicated in heme biosynthesis after 24 hours of E2 treatment as determined by microarray. 
Data are shown as fold change from wild-type. Error bars denote SEM (n = 3).  
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Figure 3.8. Expression of GATA1 NF mutants in G1ME cells. 
Western blot showing GATA1 expression in G1ME lines 72 hours after infection with wild-type or 
mutant proteins and compared to endogenous levels in MEL cells. β-actin serves as a loading 
control. Bands were quantified by densitometry and relative GATA1 levels are noted below each 
panel.  
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Figure 3.9. GATA1 NF mutations impair megakaryocytic maturation. 
(A) MGG and AChE staining of G1ME cells 72 hours after infection with wild-type or mutant 
GATA1-expressing vector. Scale bars, 20 µm. (B-C) Expression of GATA1 activated (C) and 
repressed (D) genes in FACS-purified CD42-positive megakaryocytes 72 hours after transduction 
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as determined by RT-qPCR, normalized to β-actin, and plotted as fold change from uninfected 
samples. (D-E) Average transcriptional activities of all examined activated (D, n = 10) and 
repressed (E, n = 6) genes. * P <0.05. Error bars denote SEM (n = 3) unless otherwise noted. 
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Figure 3.10. Flow cytometry analysis of G1ME cells expressing GATA1 NF mutants. 
(A) Surface expression of the terminal megakaryocyte marker CD42 and the terminal erythroid 
marker Ter119 as assessed by flow cytometry in G1ME cells 72 hours after infection with wild-
type or mutant GATA1. Dot plots (B) show a representative experiment. Percentages refer to the 
fraction of GFP-positive cells expressing CD42 or Ter119. Approximately 45% of transduced cells 
were GFP-positive. Error bars denote SEM (n = 3).  
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Figure 3.11. Binding of GATA1 NF mutants to FOG1 by co-IP. 
(A) Wild-type or mutant GATA1 was co-expressed with FLAG-tagged FOG1 in HEK-293 cells and 
analyzed by anti-FLAG IP followed by anti-GATA1 or anti-FOG1 western blotting. Input 
represents 5% of lysate. (B) Quantification of western blot signals. * P <0.05. Error bars denote 
SEM (n = 3). 
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Figure 3.12. Binding of GATA1 NF mutants to FOG1 by ITC. 
ITC data showing titration of the first zinc finger of the Drosophila FOG-family protein (dFOG-F1) 
into wild-type or mutant GATA1 NF proteins. 
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Figure 3.13. Effect of GATA1 NF mutations on FOG1 chromatin occupancy. 
Anti-GATA1 and anti-FOG1 ChIP in G1E cells expressing indicated GATA1 versions after 24 
hours of E2 treatment. (A) Anti-GATA1 ChIP at FOG1-dependent binding sites. (B) Anti-GATA1 
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ChIP at FOG1-independent binding sites that contain single (Hbb HS3, Gata2 -3.9 kb) or 
palindromic (Lyl1 prom) motifs and regulate activated (Hbb) or repressed (Gata2, Lyl1) genes. (C) 
Anti-FOG1 ChIP at FOG1-independent binding sites. (D) FOG1 ChIP signals were normalized to 
GATA1 ChIP signals at each FOG1-independent site. Error bars denote SEM (n = 3). 
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Figure 3.14. Effect of GATA1 NF mutations on mast cell genes. 
Expression of mast cell-specific genes after 24 hours of E2 treatment as determined by RT-
qPCR, normalized to β-actin, and plotted as fold change from uninfected samples. Error bars 
denote SEM (n = 3).  
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Figure 3.15. Binding of GATA1 NF mutants to DNA by ITC. 
ITC data showing the titration of wild-type or indicated mutant versions of the GATA1 NF into a 16 
base pair oligonucleotide containing a GATC motif.  
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Figure 3.16. Chromatin occupancy of GATA1 NF mutants at palindromic motifs. 
Anti-GATA1 ChIP in G1E cells expressing wild-type or mutant GATA1 after 24 hours of E2 
treatment using primers spanning single (Hbb HS2) or palindromic (all other) motifs. (A) NF 
mutations that fall on the DNA-binding surface. (B) NF mutations that fall outside the DNA-binding 
surface. Note that the reduced occupancy of V205M, G208S, G208R, and D218Y at Slc4a1 +1.6 
kb, Slc22a4 +1.2 kb, and Alad +4 kb is because GATA1 binding at these sites is FOG1-
dependent. Error bars denote SEM (n = 3). 
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Figure 3.17. Effect of GATA1 NF mutations on TAL1 complex occupancy. 
(A-D) Anti-GATA1, anti-LMO2, or anti-TAL1 ChIP in G1E cells expressing wild-type or mutant 
GATA1 after 24 hours of E2 treatment using primers as in Figure 3.13. For panels (C-D), LMO2 
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and TAL1 ChIP signals were normalized to GATA1 ChIP signals at each site. Error bars denote 
SEM (n = 3 for GATA1 and LMO2 ChIP, n = 2 for TAL1 ChIP). 
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Figure 3.18. Binding of GATA1 NF mutants to LMO2 by NMR spectroscopy. 
(A) A portion of the 1H,15N HSQC spectra of 15N-LMO2LIM2-Ldb1LID (red peaks) following addition 
of one equivalent of either GATA1 NF (green), R216Q (cyan), R216W (gold), or D218G (purple). 
(B) Relative weighted average change in chemical shift position of resonances from 15N-
LMO2LIM2-Ldb1LID following addition of wild-type or mutant GATA1 NF. Shown are the average 
shifts of three separate resonances for each series of titrations. * P <0.05. Error bars denote SD. 
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Figure 3.19. Engineered LMO2-disrupting mutations.  
(A) Western blot showing GATA1 levels in G1E cells expressing wild-type or mutant GATA1 after 
24 hours of E2 treatment. β-actin serves as a loading control. Bands were quantified by 
densitometry and relative GATA1 levels are noted below each panel. ND = not determined. (B) 
MGG and benzidine staining after 72 hours of E2 treatment. The percentage of hemoglobin-
positive cells is indicated in the upper right corner of each benzidine panel. Scale bars, 20 µm 
(left panels) and 50 µm (right panels). Compare to R216Q and D218G mutants in Figure 3.3. (C) 
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Expression of GATA1-regulated genes after 24 hours of E2 treatment as determined by RT-
qPCR, normalized to β-actin, and plotted as fold change from GATA1-expressing cells. (D) 
Hemoglobin concentrations and representative images of cell pellets after 72 hours of E2 
treatment. Compare to R216Q and D218G mutants in Figure 3.4. (E-F) Anti-GATA1, anti-FOG1, 
and anti-LMO2 ChIP after 24 hours of E2 treatment. FOG1 and LMO2 ChIP signals were 
normalized to GATA1 ChIP signals at this binding site. Error bars denote SEM (n = 3).  
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Figure 3.20. Transcriptional signatures of R216 and D218 mutation pairs. 
(A) Unsupervised hierarchical clustering of G1E cells expressing wild-type or mutant GATA1 
based on expression profiling with microarrays. Note that one D218G replicate is 
indistinguishable from the R216Q replicates. (B) Venn diagrams of direct GATA1 target genes 
significantly downregulated when compared with wild-type GATA1. (C) Expression of GATA1-
regulated genes highly sensitive to TAL1 complex disruption was validated by RT-qPCR, 
normalized to β-actin, and plotted as fold change from uninfected samples. (D) Anti-GATA1 and 
anti-LMO2 ChIP in G1E cells expressing wild-type or mutant GATA1 after 24 hours of E2 
treatment using primers against GATA1-occupied elements in genes significantly impaired in 
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response to R216Q and D218G mutations. LMO2 ChIP signals were normalized to GATA1 ChIP 
signals at each site. Error bars denote SEM (n = 3).  
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Figure 3.21. Occupancy of the R216W mutant at misregulated genes. 
Anti-GATA1 ChIP after 24 hours of E2 treatment using primers recognizing GATA1 binding sites 
at genes whose activities are at least twofold increased or decreased when compared to wild-
type GATA1-expressing cells. Error bars denote SEM (n = 3).  
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Table 3.1. Hematologic profiles of patients carrying GATA1 NF mutations. 
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Table 3.2. Erythroid GATA1 target genes examined by RT-qPCR. 
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Table 3.3. Megakaryocytic GATA1 target genes examined by RT-qPCR.  
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Table 3.4. FOG1 and DNA binding affinities of GATA1 NF mutants. 
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Table 3.5. GATA1-occupied elements examined by ChIP. 
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Table 3.6. Summary of disease-associated GATA1 NF mutations. 
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CHAPTER 4. SPLICE SITE MUTATIONS IN EXON 2 OF GATA1 IMPAIR CHROMATIN 
OCCUPANCY AT ERYTHROID GENES 
 
 
 
Research presented in this chapter was carried out in collaboration with the laboratory of Stella 
Chou. Complementary experiments performed in human cells (discussed in Chapter 5) were 
executed by Daniel VanDorn and Philip Arca, research technicians in the Chou lab, with 
bioinformatic expertise provided by Marta Byrska-Bishop, a graduate student in the Ross 
Hardison laboratory.   
This work is included in its entirety in the following manuscript, currently in preparation. Daniel 
VanDorn, Marta Byrska-Bishop, Amy E. Campbell, Philip R. Arca, Yu Yao, Gerd A. Blobel, Paul 
Gadue, Fernando Costas, Richard L. Nemiroff, Deborah L. French, Ross C. Hardison, Mitchell J. 
Weiss, Stella T. Chou. Patient-derived induced pluripotent stem cells reveal distinct 
hematopoietic defects conferred by truncated GATA1. 
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Introduction 
GATA1 is an essential transcription factor for megakaryocyte and erythroid cell development, 
where it acts to regulate lineage-specific gene expression (Fujiwara et al., 1996; Shivdasani et al., 
1997). In normal hematopoiesis, GATA1 is alternatively spliced to produce two isoforms: a 
predominant full-length protein that includes exon 2, and a truncated isoform called GATA1s that 
lacks this exon and therefore the first 83 amino acids (Calligaris et al., 1995) (Figure 1.3). 
Germline splice site mutations in the GATA1 gene that result in almost exclusive expression of 
GATA1s have been identified in patients with congenital dyserythropoietic anemia, in which 
affected individuals exhibit moderate to severe anemia and neutropenia, but no abnormalities in 
platelet number (Hollanda et al., 2006). More recently, whole exome sequencing of Diamond 
Blackfan anemia (DBA) patients revealed a similar inherited splice site mutation in GATA1 
(Sankaran et al., 2012). In contrast, individuals with trisomy 21 acquire GATA1s mutations in the 
setting of two clonal hematopoietic disorders, TMD and AMKL (Alford et al., 2011; Wechsler et 
al., 2002). Notably, euploid patients with anemia due to inherited GATA1s mutations are not 
predisposed to leukemia.  
The N-terminus of GATA1, which is absent in GATA1s, houses a transcriptional activation 
domain identified by virtue of its ability to turn on reporter gene expression in non-hematopoietic 
cells (Calligaris et al., 1995; Martin and Orkin, 1990). However, the NAD seems to be dispensable 
for GATA1 function in several models of hematopoiesis (Kuhl et al., 2005; Weiss et al., 1997). 
Additionally, and in contrast to the severe anemia and early death seen in GATA1-null mice 
(Fujiwara et al., 1996), mice genetically engineered to express only GATA1s exhibit anemia and 
abnormal megakaryopoiesis during fetal development, but have normal adult hematopoiesis (Li et 
al., 2005). Thus, the function of the GATA1 NAD appears to be context-dependent according to 
cell type, species, and ontogeny.  
In order to better understand the role of the GATA1 NAD in erythromegakaryocytic 
development and disease, we utilized the G1ME cell gene complementation system (see Chapter 
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1). Using this system, we find that loss of the GATA1 N-terminus markedly impairs erythroid 
development and redirects progenitors to a megakaryocytic fate. This lineage-specific defect 
appears to be due to the fact that GATA1s binding is reduced at erythroid target genes but 
normal at megakaryocyte genes, an insight that provides a novel mechanism to explain human 
anemias associated with GATA1s mutations.  
 
Results 
The N-terminus of GATA1 is required for normal erythroid maturation 
To determine the capacity of N-terminally truncated GATA1 to promote erythroid and 
megakaryocyte maturation, we studied the function of GATAs in the hematopoietic G1ME cell 
line. G1ME cells were derived from in vitro differentiation of murine GATA1-null embryonic stem 
cells and self renew in culture as TPO-dependent, undifferentiated blasts (Stachura et al., 2006). 
When cultured in the presence of both TPO and EPO, cells reconstituted with GATA1 undergo 
terminal erythroid and megakaryocyte maturation (Chou et al., 2009; Stachura et al., 2006). We 
introduced wild-type or mutant GATA1 into G1ME cells and assessed differentiation by 
morphology and flow cytometry for lineage-specific cell surface markers. Four days after 
transduction, cells reconstituted with wild-type GATA1 expressed the erythroid and 
megakaryocyte surface markers Ter119 and Gp1b at a ratio of approximately 3 to 1 (Figure 4.1). 
These cells had also acquired morphological characteristics of mature erythrocytes, including 
condensed nuclei and a lightly staining cytoplasm, and mature megakaryocytes, including 
increased cell size and multilobular nuclei (Figure 4.1). In contrast, G1ME cells expressing 
GATA1s showed a marked deficiency in erythroid differentiation but robust megakaryocyte 
maturation (Figure 4.1). They expressed Ter119 and Gp1b at a ratio of about 0.6 to 1. In addition 
to a reduction in the number of Ter119-positive cells, the intensity of Ter119 expression was 
reduced. Furthermore, the erythroid cells that were present had large nuclei and a darkly staining 
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cytoplasm, indicating that they were less mature than their wild-type counterparts. GATA1 and 
GATA1s-expressing megakaryocytes were indistinguishable.  
The effects of GATA1s on erythromegakaryocytic differentiation are consistent with the 
phenotypes of patients harboring germline GATA1s mutations. These findings validate the use of 
the G1ME gene complementation system as a faithful and robust model with which to study 
disease-causing GATA1 mutations. 
 
Differential occupancy of GATA1s at erythroid and megakaryocyte target genes 
We next wanted to determine the mechanism(s) by which GATA1s expression leads to 
defective erythropoiesis. Although the NAD is not required for DNA binding in vitro (Martin and 
Orkin, 1990), several other germline GATA1 mutations also not predicted by in vitro or structural 
studies to impair DNA binding have been shown to affect the ability of GATA1 to bind to target 
sites in vivo (Campbell et al., 2013; Chlon et al., 2012; Letting et al., 2004). Therefore, we 
hypothesized that loss of the NAD might impair GATA1 chromatin occupancy selectively at 
erythroid genes. To test this, we carried out ChIP on G1ME cells 48 hours after transduction. At 
this time point, maturation differences between GATA1 and GATA1s-expressing cells were not 
yet present (Figure 4.1) and both proteins were expressed equivalently (Figure 4.2). Anti-HA 
ChIP revealed that GATA1 and GATA1s occupied megakaryocyte genes equivalently, but that 
GATA1s showed a >40% reduction in binding to erythroid genes (Figure 4.3). Gene expression 
changes as determined by RT-qPCR analysis were consistent with these occupancy profiles, with 
erythroid target genes displaying reduced transcriptional activation in GATA1s-expressing cells 
while megakaryocyte target genes were induced at least as robustly as by wild-type GATA1 
(Figure 4.4).  
Together, these data suggest that deletion of the first 83 amino acids of GATA1 can diminish 
GATA1 chromatin occupancy specifically at erythroid target genes, leading to impaired 
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erythropoiesis. This suggests a new mechanism to help explain the anemic phenotypes found in 
patients harboring GATA1s mutations.  
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Figure 4.1. GATA1s impairs erythroid differentiation. 
The left panels depict surface expression of the terminal megakaryocyte marker Gp1b and the 
terminal erythroid marker Ter119 as assessed by flow cytometry in G1ME cells two and four days 
after infection with GATA1 or GATA1s. Percentages refer to the fraction of GFP-positive cells 
expressing Gp1b or Ter119. Greater than 90% of transduced cells were GFP-positive. The right 
panels show MGG staining of G1ME cells expressing GATA1 or GATA1s four days after 
transduction. Scale bars, 20 µm. 
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Figure 4.2. Expression of GATA1 and GATA1s in G1ME cells. 
Anti-HA and, as a loading control anti-β-actin western blots of extracts from G1ME cells 
expressing GATA1 or GATA1s 48 hours after transduction. Bands were quantified by 
densitometry and relative GATA1 levels are noted below the panel. ND = not determined. 
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Figure 4.3. GATA1s chromatin occupancy at erythroid and megakaryocyte genes. 
Anti-HA or anti-IgG (control) ChIP in G1ME cells expressing GATA1 or GATA1s 48 hours after 
transduction using primers recognizing erythroid- or megakaryocyte-specific target genes. Upper 
panels depict binding at individual gene targets. Lower panel shows the average binding across 
all examined erythroid or megakaryocyte (Meg) genes. The occupancy of wild-type GATA1 has 
been set to 1 in all cases. ** P <0.005. Error bars denote SEM or SD (n = 4 for upper panels and 
n = 10 for lower panel).  
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Figure 4.4. Effect of GATA1s on erythroid and megakaryocyte gene expression. 
Expression of GATA1-activated erythroid (top row) and megakaryocyte (bottom row) genes 48 
hours after transduction with GATA1 or GATA1s as determined by RT-qPCR, normalized to β-
actin, and plotted as fold change from uninfected samples. * P <0.05. Error bars denote SEM (n = 
4).  
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Myriad human diseases are caused by defects in the regulatory factors that control gene 
expression. Yet our understanding of the mechanistic consequences of these defects is far from 
complete. In this work, we focus our attention on the tissue-specific transcription factor GATA1. 
Mutations in GATA1 cause a spectrum of hematologic disorders, but the mechanisms by which 
these mutations alter GATA1 function and lead to disease are unclear.  
In the first part of this work, we show that missense mutations in the GATA1 NF impair 
association with the essential cofactors FOG1 and the TAL1 complex. FOG1-disrupting mutations 
result in greatly reduced transcriptional activation and repression, which severely impairs 
erythroid and megakaryocyte maturation and leads to pronounced clinical phenotypes. In 
contrast, mutations that disrupt TAL1 complex binding only moderately inhibit transcriptional 
activation, resulting in subtle defects to erythroid and megakaryocyte development that cause 
relatively mild disease presentations. Remarkably, different substitutions at the same residue can 
selectively inhibit TAL1 complex or FOG1 binding, producing distinct cellular and clinical 
phenotypes. Perhaps most surprisingly, we reveal that mutations in the DNA-binding surface of 
the NF do not affect GATA1 occupancy at gene targets in vivo, and therefore cause disease 
through alternate mechanisms (Figure 5.1). (For a summary of all results regarding GATA1 NF 
mutations, see Table 3.6.) 
In the second part of this work, we extend our studies in an effort to understand how splice 
site mutations in exon 2 of GATA1 cause human disease. Splice site defects lead to the 
production of an amino-truncated protein called GATA1s, which we demonstrate displays 
reduced binding at erythroid genes while occupying megakaryocyte-specific genes normally. 
Reduced erythroid gene occupancy impairs normal red blood cell development and suggests a 
mechanism for the anemia found in patients with these mutations (Figure 5.2).  
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In the following sections, these conclusions will be discussed in greater depth and follow-up 
experiments will be suggested to expand the work in new directions. 
 
A majority of GATA1 NF mutations disrupt FOG1 binding 
Four out of seven GATA1 NF mutations disrupt binding to the cofactor FOG1. Our studies 
establish a strong correlation between binding to full-length FOG1 in vitro, recruitment of FOG1 to 
target sites in vivo, facilitating GATA1 chromatin occupancy at FOG1-dependent sites, the ability 
to trigger G1E and G1ME differentiation, and disease severity in patients. This solidifies the idea 
that reduced FOG1 binding underlies one major class of disease-causing GATA1 mutations. 
Future efforts could address ways to specifically rescue the effects of FOG1-disrupting mutations, 
and use this knowledge to create targeted therapies for patients with this type of defect.   
Early work from the Orkin laboratory used a split two-hybrid system in yeast to first select for 
engineered mutations in GATA1 that cripple association with FOG1, and then to find mutations in 
FOG1 that restore the interaction (Crispino et al., 1999). The GATA1 mutant V205G (an alteration 
very similar to disease-causing V205M) led to impaired FOG1 binding and erythroid maturation 
that were rescued by expression of compensatory mutant FOG1 S706R. One could determine if 
FOG1 S706R restores the differentiation, binding, occupancy, and transcriptional defects caused 
by GATA1 V205M. If so, does it also rescue G208S, G208R, and D218Y defects? We predict that 
FOG1 S706R will rescue all of these GATA1 mutants because S706R creates a de novo GATA1-
FOG1 interaction site rather than specifically binding V205G (Crispino et al., 1999). However, if 
these GATA1 mutants require unique compensatory mutations in FOG1, a split two-hybrid 
approach in the model of Crispino et al. could be utilized to find them. In the end, appropriate 
FOG1 mutants could be introduced into a patient’s own HSCs under erythroid- and 
megakaryocyte-specific promoters that drive expression in the correct cells. Alternatively, 
genome-editing technologies could be used to directly correct the disease-causing mutations in 
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the endogenous GATA1 locus. These approaches would eliminate the need for matched donors 
and reduce complications such as infection and rejection that commonly occur with bone marrow 
transplant (for now the only curative option for GATA1 mutant patients). Even a moderate 
restoration of the GATA1-FOG1 interaction could have a marked effect on phenotype, as 
demonstrated by our comparisons of G208 mutations. 
 
If DNA-binding residues of the GATA1 NF aren’t binding DNA, what are they doing? 
Given strong in vitro evidence that mutations on the GATA1 NF DNA-interacting surface (R216Q 
and R216W) impair binding to palindromic and GATC motifs (this study and (Yu et al., 2002)), it 
was surprising that they do not affect GATA1 target site occupancy in vivo. Similar discrepancies 
in the context of a distinct GATA1 mutant have been noted (Lamonica et al., 2006). This apparent 
discordance highlights the importance of validating in vitro studies with in vivo experiments. It 
remains possible that subtle deficiencies in DNA binding, should they exist, are missed by ChIP-
qPCR or are revealed only at sites not included in our analysis. Genome-wide localization of the 
R216Q and R216W mutants should address these points in future studies. It is also possible that 
cofactor complexes surrounding GATA1 help stabilize it within chromatin, thereby compensating 
for the loss of direct DNA binding by the NF, or that the NF simply does not contribute to DNA 
binding in vivo as much as originally assumed. Importantly, our work provides an alternative 
explanation for R216Q, which does not impair DNA binding as predicted, but rather inhibits TAL1 
complex recruitment to GATA1-occupied genes (see also below).  
On the other hand, the mechanism by which R216W affects GATA1 function remains 
unclear, as we failed to observe any measurable impact on DNA, FOG1, or TAL1 complex 
binding. There was also no change to the occupancy profiles of several other GATA1 cofactors 
(CBP/p300 and Cdk9, data not shown). Notably, this mutation does result in a subtle erythroid 
phenotype in cells – slightly but significantly reducing transcriptional activation and repression. 
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Therefore, our current working hypothesis is that residue R216 makes contact with an as yet 
untested or undescribed GATA1 cofactor, and that the R216W mutation selectively disrupts this 
interaction (Figure 5.1). An untested candidate is EKLF. The lack of a ChIP-grade antibody 
recognizing endogenous EKLF prevented us from determining if R216W affects EKLF chromatin 
occupancy. Future studies to address this question could be carried out with exogenously 
expressed, tagged EKLF. If this yields no definitive answer, we propose an unbiased IP-mass 
spectrometry screen to identify unknown GATA1-interacting partners whose binding is disrupted 
by R216W. It is also possible that the R216W mutation creates a binding site for a protein that 
does not normally associate with GATA1. IP-mass spectrometry could be used address this 
hypothesis as well.  
Our existing data does not explain how the R216W mutation might lead to a presentation of 
CEP. Gene expression analyses in erythroid cells provided no immediate clue other than a ~50% 
decrease in Uros expression. However, because CEP in humans is associated with much less 
than 50% UROS activity, this is unlikely to account for the observed patient phenotype. Although 
it is possible that a lack of any major identifiable deficiencies in R216W-expressing cells reflects a 
limitation of our assays, it is important to note that this mutation was identified in a single patient 
with additional genetic abnormalities and co-morbidities, leaving open the possibility that the 
effects of R216W are influenced by genetic modifiers.  
Setting aside patient-derived mutations, more generally there is still an open question as to 
whether or not any of the structurally defined GATA1 NF DNA-binding residues are important for 
chromatin occupancy in vivo. Can changes to these residues impair occupancy at palindromic 
and GATC motifs? To determine this, we could engineer mutations in known DNA-interacting 
residues such as P213, L214, N226, or Y231, express these altered proteins in G1E cells, and 
carry out GATA1 ChIP at the same sites interrogated in this document. If occupancy (compared 
to wild-type GATA1) is decreased at palindromic sites but normal at single motifs, this would 
suggest the NF might indeed play a role in stabilizing DNA binding in vivo. Unpublished results 
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describing an anemic and thrombocytopenic “knock-in” mouse harboring a P213G mutation 
indicate this may be the case (Yu et al., 2002). Of course, ruling out the possibility that any 
observed effects are indirectly due to reduced cofactor binding is critical. 
 
A new role for the TAL1 complex in GATA1-mediated disease 
An unexpected finding from our work is that R216Q and D218G disrupt the interaction between 
GATA1 and the TAL1 cofactor complex. We therefore implicate the TAL1 complex in non-
malignant hematopoietic disease for the first time. This result was not predicted by prior in vitro or 
structural studies, and is surprising given that R216Q falls on the DNA-binding surface and 
D218Y disrupts FOG1 association. However, a shared molecular defect is consistent with the 
similar phenotypes caused by R216Q and D218G mutations. Further, a qualitative difference in 
TAL1 complex binding between R216Q and R216W, and between D218G and D218Y, explains 
each pair’s divergent patient presentations. 
Notably, GATA1 mutations that affect TAL1 complex binding neither measurably diminish nor 
increase FOG1 recruitment and vice versa, arguing that these proteins do not mutually stabilize 
or interfere with each other as has been suggested by co-IP experiments (Rodriguez et al., 2005) 
and consistent with in vitro data showing simultaneous binding of FOG1 and LMO2 to the GATA1 
NF (Wilkinson-White et al., 2011).  
Relatively few genes are misregulated by the R216Q or D218G mutations, in agreement with 
prior studies demonstrating limited alterations upon perturbation of the TAL1 complex (Fujiwara et 
al., 2010; Tripic et al., 2009) and in contrast to FOG1 which changes the expression of substantial 
numbers of genes. These modest transcriptional effects and the relatively mild phenotype they 
cause are likely because the TAL1 complex is mostly dispensable for GATA1 chromatin 
occupancy and gene repression. An outstanding question remains: do these misregulated targets 
reveal a specific cellular process uniquely affected by disruption of the GATA1-TAL1 complex? 
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Based on previously published data, one might predict that signatures for erythroid membrane 
organization or heme biosynthesis would be uncovered (Kassouf et al., 2010). However, 
preliminary functional annotation and gene set enrichment analyses failed to identify any gene 
ontology class or pathway uniquely enriched in R216Q or D218G cells relative to other mutant 
lines. Future studies might expand these bioinformatic efforts in an attempt to define a class of 
genes whose expression is specifically reliant on the TAL1 complex. 
 
How do different mutations at the same residue selectively disrupt cofactor binding? 
A remarkable finding of our study was that distinct substitutions at a single residue can lead to not 
only quantitative changes (G208S vs. G208R) but also qualitative differences (D218G vs. D218Y 
and R216Q vs. R216W) in cofactor binding. We speculate that each substitution in R216 or D218 
elicits unique phenotypes as a result of different physiochemical properties. Although both R216 
mutations remove the positively charged side chain, glutamine substitution trims down the side 
chain whereas tryptophan substitution introduces a bulky residue that has the potential to form 
stabilizing cation-π interactions. Thus, the smaller R216Q likely results in minor rearrangements 
that shift the GATA1-binding surface away from LMO2, whereas the bulkier R216W is able to 
maintain the surface. Similarly, although both D218 mutations eliminate key hydrogen bonds that 
likely cause focal changes to the NF structure, conversion to glycine introduces backbone 
flexibility that could disrupt the LMO2 binding site, whereas mutation to tyrosine introduces a 
bulky side chain that could preserve the LMO2-binding surface but would necessitate some 
repacking of the surrounding side chains, disrupting the nearby FOG1-binding surface (Figure 
5.3). 
A direct test of these predictions would necessitate solving the structure of the GATA1-
FOG1-LMO2 interaction, a feat as yet unaccomplished by anyone. This structure could then be 
compared to those obtained with mutant forms of GATA1 to map the exact changes that occur 
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between the three proteins in the presence of missense mutations. An alternative approach might 
be to design GATA1 proteins harboring R216 and D218 mutations that are similar in form to the 
disease-causing ones, express them in G1E and G1ME cells, and assess maturation, gene 
expression, chromatin occupancy, and cofactor binding for phenocopy effects. If the structural 
assumptions made above were true, one would predict that D218A would mimic D218G, D218F 
would copy D218Y, and R216N would imitate R216Q.  
 
Aberrant GATA1s expression causes erythroid-specific defects 
Our work demonstrates that loss of the N-terminus reduces GATA1 occupancy specifically at 
erythroid target genes, leading to markedly impaired red blood cell development. Future studies 
will expand these investigations genome-wide and into other cell systems (discussed below).  
Contrary to our findings, the NAD has been described as dispensable for GATA1 function in 
erythrocytes (Weiss et al., 1997). This discrepancy could arise from the particular cell systems 
used and/or the specific deletions made. The earlier study was carried out in an erythroid-
committed cell line, whereas ours was done in bipotential erythromegakaryocytic G1ME cells. 
This suggests that the NAD plays a critical role during MEP lineage choice to promote the 
erythroid fate, but may be less important in terminal erythroid maturation. We can test this by 
expressing GATA1 and GATA1s in G1E cells, and examining cellular maturation, gene 
expression, and chromatin occupancy profiles. Additionally, the earlier study removed only the 
first 63 amino acids of the GATA1 N-terminus, compared to our human-disease derived deletion 
of 83 residues. This suggests that an essential function is housed within these 20 remaining 
amino acids. In particular, we suspect they might comprise an important protein-protein 
interaction site. To determine the role of these 20 residues in erythroid differentiation, we can 
repeat our maturation, gene expression, and chromatin occupancy experiments comparing 
GATA1, GATA1s(Δ1-83), and GATA1(Δ1-63) side-by-side.  
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The exact mechanisms by which deletion of the NAD reduces GATA1 chromatin occupancy 
are unclear. We do not expect this domain to have direct effects on DNA binding. Therefore, our 
working model is that the NAD makes contact with an erythroid-specific cofactor that is important 
for stabilizing GATA1 binding at target sites and activating transcription (Figure 5.2). When the 
NAD is missing, this cofactor cannot bind and GATA1 occupancy and gene activation are 
reduced. Megakaryocytes are not sensitive to loss of the NAD because they do not express this 
cofactor or use the NAD to facilitate DNA binding. Protein interactions mediated by the NAD 
remain relatively unexplored. RB is known to bind (Kadri et al., 2009) and has been shown to 
facilitate an open chromatin state at major histocompatibility complex genes (Osborne et al., 
1997). We plan to ChIP for RB in GATA1- and GATA1s-expressing G1MEs at erythroid and 
megakaryocyte genes to determine if it might play a role in facilitating occupancy at the former. 
To identify other potential NAD-associated factors, in the future we plan to carry out an unbiased 
IP-mass spectrometry screen to identify proteins that fail to associate with GATA1s, but bind 
GATA1 in erythroid cells. If residues 64-83 are found to be important in the proposed maturation 
studies, this will further inform our interaction screen. 
 
Can individual gene studies be extrapolated genome-wide? 
Almost all of the studies discussed in this document were carried out by examining expression of 
and factor occupancy at several dozen GATA1-regulated genes. We fully expect the conclusions 
made based on these individual targets to hold up when global analyses are carried out. 
For GATA1 NF mutants, expression profiling on a wide scale by microarray has been 
completed and supports results from RT-qPCR experiments (see Chapter 3). Future GATA1, 
FOG1, LMO2, and TAL1 ChIP-sequencing will establish the models proposed here on a whole 
genome level. We do keep in mind that in looking genome-wide we might also discover 
something novel, as was the case for a recently published study of GATA1 occupancy in 
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megakaryocytes (Chlon et al., 2012). Only once these high-throughput sequencing experiments 
are done will we know for sure.   
As a continuation of our GATA1s studies, we are examining the transcriptomes of GATA1- 
and GATA1s-expressing cells harvested two days after transduction by microarray. Our 
preliminary results support the conclusions made after inspecting only a handful of GATA1 
targets; namely, that erythroid genes display reduced transcriptional activation in GATA1s-
expressing cells while megakaryocyte genes are induced more robustly (Figure 5.4). We are also 
in the process of examining GATA1 and GATA1s occupancy genome-wide by ChIP-sequencing. 
Once we have this data, we will carry out a differential binding analysis using the DiffBind 
package in R to determine if there is statistically significant difference in binding between GATA1 
and GATA1s at erythroid genes but not megakaryocyte genes at the whole genome level, 
consistent with what we observe by ChIP-qPCR.  
 
Systems for studying disease-causing mutations 
Previous studies of GATA1 NF mutations relied mostly on in vitro assays (Freson et al., 2001; 
2002; 2003; Mehaffey et al., 2001; Nichols et al., 2000; Yu et al., 2002), with only two mutants 
(V205M and R216Q) examined in any cell-based system (Letting et al., 2004; Nichols et al., 
2000; Yu et al., 2002). In contrast, prior studies of GATA1s, though limited, were predominantly 
carried out in vivo (Kuhl et al., 2005; Li et al., 2005; Martin and Orkin, 1990; Weiss et al., 1997). 
Notably, all of the work to date, including research described in this document, has been done in 
murine systems. As our efforts here demonstrate, it is vitally important to pair any in vitro studies 
of disease-causing mutations with cellular and/or animal models. But which systems are best? In 
the case of GATA1, the G1E and G1ME gene complementation assays mimic patient phenotypes 
quite faithfully. These systems afford a homogeneous cellular and genetic background that allows 
for the detection of subtle defects that may be masked in studies of heterogeneous patient 
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samples; and it is also quite easy to collect large quantities of material for biochemical 
experiments and whole genome analyses. Using these two cell lines, we were able to uncover 
previously unappreciated mechanisms for GATA1 mutations that were not predicted from in vitro 
studies or structural considerations. Despite their demonstrated usefulness, the G1E and G1ME 
systems have some limitations as reflected in subtle phenotypic discrepancies between cells and 
patients. For example, the G208S mutation causes mild dyserythropoiesis without anemia in 
patients but in G1E cells produces more pronounced defects (see Chapter 3 and (Mehaffey et al., 
2001)). Furthermore, the mild thalassemia seen in some R216Q patients is not recapitulated in 
G1E cells (see Chapter 3 and (Yu et al., 2002)). These variations might be rooted in species 
differences or the fact that these systems to not recapitulate all stages of erythromegakaryocytic 
maturation. Future experiments confirming the results from G1E and G1ME cells in whole animal 
models and/or human systems would increase confidence in our proposed models. Below are 
some preliminary results from human systems that validate our findings from murine cell lines.  
We first attempted to corroborate our results using primary hematopoietic material obtained 
from affected human individuals. This was a challenge, as diseases caused by GATA1 mutations 
are rare and therefore so are patient samples. Compounding this was the reality that several 
patients had passed away or undergone curative bone marrow transplants. Furthermore, we were 
unable to request collection of required material from individuals with mild phenotypes as it was 
medically unnecessary. Finally, several samples that were available were of inadequate quality to 
be of use in cell culture experiments. Even if we had successfully obtained primary tissue, it 
would have been in quantities insufficient to carry out key biochemical and ChIP experiments 
needed to confirm molecular mechanisms suggested by the G1E and G1ME experiments. 
In lieu of primary hematopoietic material, we sought to generate induced pluripotent stem 
cells (iPSCs) from patient fibroblasts or peripheral blood that could be differentiated in culture for 
further study. The laboratory of Dr. Stella Chou at The Children’s Hospital of Philadelphia carried 
out these iPSC experiments. All iPSCs derived from a patient harboring the V205M mutation 
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displayed numerous, unique karyotypic abnormalities that were acquired during reprogramming. 
These abnormal iPSCs were not analyzed further. In contrast, we were able to generate 
karyotypically normal iPSCs from peripheral blood-derived mononuclear cells from one patient 
with a germline GATA1 exon 2 mutation. To determine the effect of GATA1s on hematopoiesis in 
this system, we generated embryoid bodies (EBs) in defined media containing sequential 
combinations of cytokines to induce primitive streak/mesoderm formation followed by 
hematopoietic specification (Chou et al., 2012) (Figure 5.5A). On days 7-8 of EB differentiation, 
hematopoietic progenitors co-expressing CD43+41+235+ were present in EB cultures (Figure 
5.5B), and by day 12 of differentiation monolineage hematopoietic cells released from EBs were 
erythroid (CD235+41-), myeloid (CD45+18+), or megakaryocytic (CD41+42+) (Figure 5.5C). 
GATA1s iPSCs produced multipotent progenitor populations (CD43+41+235+) at similar levels 
compared to lines with wild-type GATA1 (Figure 5.5B,D), but GATA1s progenitors failed to 
differentiate into CD235+41- erythroblasts despite retained capacity for myeloid and 
megakaryocytic differentiation (Figure 5.5C,E). Morphologic examination of suspension cells of 
day 20 EB cultures showed numerous late stage erythroblasts derived from GATA1 iPSCs that 
were lacking in cultures derived from GATA1s iPSCs (Figure 5.5F).  
In summary, we obtained very similar results regarding the effect of GATA1s on erythroid 
maturation from both human iPSCs and murine G1ME cells. Whether comparable gene 
expression changes and occupancy profiles are present in the human cells is as yet 
undetermined. While the former question can be addressed with microarray or single-cell PCR 
analyses, we are unable to generate sufficient quantities of material for the ChIP experiments that 
would address the latter. With current technologies, this is an inherent limitation of the iPSC 
system. Another drawback to this model is that hematopoietic developmental potential varies 
between iPSC clones, likely due to genetic differences in the subjects from which the iPSCs are 
derived (Choi et al., 2009; Mills et al., 2013). This may render the study of mutations that produce 
subtle phenotypes (like R216Q, R216W, and D218G) a challenge. In terms of GATA1s, this 
variation requires that iPSCs be derived from additional affected individuals before strong 
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conclusions are drawn. In all cases, it would be most rigorous to use genome editing to generate 
isogenic iPSC lines that differ solely at the disease-associated nucleotide (Soldner et al., 2011). 
This engineering-based approach may present a solution to the problem of unavailable GATA1 
NF mutant patient samples, and allow us to create iPSC lines that recapitulate any described 
GATA1 mutation. 
 
Do other germline GATA1 mutations exist? 
The frequency of germline GATA1 mutations is unknown. Since the first description in 2000, less 
than 15 families have been reported. Are these lesions extremely rare, or are physicians failing to 
identify them? Until knowledge of GATA1-mediated disorders becomes more widespread in the 
hematology community, they are liable to be underreported. Further, patients presenting with 
symptoms (especially mild ones such as those caused by defects in LMO2 binding) but lacking a 
clear X-linked inheritance pattern are likely to escape correct genetic diagnosis. Therefore, it is 
probable that many individuals with unexplained hematologic defects are harboring undiscovered 
GATA1 mutations. Accurately identifying people with GATA1 mutations allows clinicians to better 
estimate their disease prognosis and prevents unnecessary treatments such as immune therapy, 
splenectomy and steroids, to which GATA1 mutant patients are usually unresponsive. New 
knowledge and improving technologies should allow future hematologists to tailor patient care to 
mutation status.  
Moving forward, targeted sequencing of the GATA1 gene should be routinely incorporated 
into the workups of individuals with anemia and thrombocytopenia of unknown origin. Beyond this 
candidate gene approach, the increasing clinical application of whole-exome and whole-genome 
sequencing technologies promises to uncover GATA1 mutations medical practitioners did not 
even know they were looking for. The discovery of new GATA1 mutations may lead to the 
identification of novel GATA1 cofactors or interaction surfaces, telling us as much about basic 
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biology as disease. Of note, all currently identified defects in GATA1 cause discrete changes to 
protein function, leaving relatively strong residual activities. We hypothesize that this will be true 
for all future discoveries as well. More drastic alterations, such as mutations in the primary DNA-
binding CF domain, would very likely not be compatible with life. 
Despite hurdles to diagnosis, astute clinicians have recently used targeted sequencing to find 
unique GATA1 mutations. David Anstee’s group in the United Kingdom recently described a 
missense mutation in the termination codon (Singleton et al., 2013), the first ever noted alteration 
in the C-terminal portion of GATA1. We hypothesize that this mutation extends the GATA1 open 
reading frame, creating an elongated protein with altered cofactor binding potential. Additionally, 
just last month Kathleen Freson and colleagues in Belgium reported a third missense mutation in 
codon 218, one that changes the normal aspartic acid to an asparagine (Hermans et al., 2013). 
Previously described mutations at this residue disrupt FOG1 binding (D218Y) or LMO2 binding 
(D218G), and lead to severe or moderate phenotypes. Based on the mild thrombocytopenia 
described by Hermans et al., we would hypothesize that D218N mimics D218G and selectively 
disrupts LMO2 binding. Future experiments will utilize the G1E and G1ME gene complementation 
systems to address these two hypotheses.  
Whole-exome sequencing is also already demonstrating that additional GATA1 mutations 
exist. Vijay Sankaran and Hanna Gazda at Harvard Medical School sequenced DNA from ~60 
DBA patients without known pathogenic lesions and uncovered two additional germline exon 2 
splice site changes that lead to production of amino-truncated GATA1 (Sankaran et al., 2012). 
The work on GATA1s presented in this document will help inform the molecular etiology of 
anemias caused by these splice site mutations.  
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What can we learn about mutations in other GATA family members? 
In addition to GATA1, there are five other GATA proteins. GATA2 and GATA3 are expressed 
predominantly within the hematopoietic system, while GATA4, GATA5, and GATA6 are 
expressed outside of the blood in mesoderm and endoderm derived tissues such as the heart, 
intestine, and lung. The zinc finger regions are highly homologous between GATA factors, though 
conservation is low throughout the rest of the protein (Orkin, 1992). Like GATA1, GATA2, 
GATA3, GATA4, GATA5 and GATA6 associate with FOG1 (or the closely related FOG2) (Cantor 
and Orkin, 2005). Additionally, GATA2 and GATA3 have been shown to bind to the TAL1 
complex (Ono et al., 1998; Osada et al., 1995). Because the NF itself and its cofactor interactions 
are conserved, what we have learned about GATA1 protein interactions through our studies may 
be transferable to other GATA factors and their disease-causing mutations. Future investigations 
could explore the effects of NF mutations in GATA2 (Dickinson et al., 2011; Greif et al., 2012; 
Hsu et al., 2011; Ostergaard et al., 2011; Pasquet et al., 2013), GATA3 (Gaynor et al., 2009; 
Nesbit et al., 2004), GATA4 (Lourenço et al., 2011; Reamon-Buettner and Borlak, 2005), or 
GATA5 (Gu et al., 2012; Wei et al., 2013) on DNA and cofactor binding to better link molecular 
mechanism to disease phenotype. 
 
In summary, this work sheds new light on the pathophysiology and mechanisms underlying 
congenital hematologic diseases caused by mutations in the essential, tissue-specific 
transcription factor GATA1. This deeper understanding should improve classification, refine 
clinical management of affected individuals, and allow prediction of disease progression based on 
molecular defect. More broadly, we provide a paradigm for better understanding disease-causing 
mutations through a combined modality approach. Because mechanisms predicted by in vitro 
studies may not always reflect events in biologically relevant contexts, in vivo studies such as 
those reported here serve to not only validate predictions but also provide entirely new and 
unexpected insights. Our approach could be applied in other contexts where gene mutations lead 
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to variable clinical presentations, and underlying effects on protein function are incompletely 
understood. 
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Figure 5.1. GATA1 NF mutations disrupt cofactor binding: a summary model. 
Wild-type GATA1 binds chromatin, activating the transcription of lineage-specific genes (arrow at 
right) and repressing transcription of genes associated with proliferative states and alternative 
lineages (bar at left), leading to normal erythroid and megakaryocyte maturation. When mutations 
(green star) disrupt FOG1 binding (V205M, G208S, G208R, D218Y), chromatin occupancy is 
reduced at some binding sites, transcriptional activation and repression are greatly impaired 
(green X), and erythroid and megakaryocyte maturation are severely affected, leading to deep 
anemia and thrombocytopenia. When mutations disrupt TAL1 complex binding (R216Q, D218G), 
transcriptional activation is moderately impaired and erythroid and megakaryocyte maturation are 
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somewhat inhibited which leads to anemia and thrombocytopenia. We hypothesize that the 
R216W mutation disrupts binding to an unknown cofactor (question mark), mildly reducing 
transcriptional activation and repression to cause erythroid porphyria and thrombocytopenia. NF, 
N-terminal zinc finger; CF, C-terminal zinc finger. 
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Figure 5.2. GATA1s impairs erythropoiesis: a summary model. 
Wild-type GATA1 (left panel) associates via the NAD with an unknown erythroid-specific factor 
important for stable GATA1 chromatin occupancy and erythroid gene activation. In this cellular 
context, normal maturation of both red blood cells and megakaryocytes occurs. Mutant GATA1s 
(right panel) lacks the NAD and therefore fails to bind the aforementioned erythroid-specific 
factor. This leads to reduced GATA1 chromatin occupancy and transcriptional activation at 
erythroid genes, impairing red blood cell development. NAD, N-terminal activation domain; MK, 
megakaryocyte. 
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Figure 5.3. Possible physical causes of differential effects of R216 and D218 mutations. 
GATA1 NF (grey; surface representation), FOG1 (cyan; surface representation), LMO2-Ldb1 
(orange; surface representation). (A-C) R216 mutations. Wild-type R216 shown in red, Q216 
shown in purple, and W216 shown in magenta. Whereas the R216W mutation is similar in size to 
the wild-type side chain, and may be stabilized by various new interactions as indicated (dashed 
lines), the R216Q mutation is smaller leading to possible collapse of the LMO2-binding face 
(black arrow) due to repacking of side chains. (D-F) D218 mutations. Wild-type D218 (red), G218 
(purple), and Y218 (magenta). D218G truncates the side chain and introduces flexibility into the 
backbone, leading to possible collapse of the LMO2-binding face (black arrow) due to repacking 
of the side chains. The larger D218Y mutation could maintain the position of the LMO2-binding 
face, but require repacking of the small hydrophobic core of the NF (black arrow) leading to 
disruption of the FOG1-binding face. Models are based on the coordinates of PDB accession 
code 2L6Z. NF, N-terminal zinc finger; WT, wild-type. 
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Figure 5.4. Gene set enrichment analysis of G1ME microarray data. 
Gene set enrichment analysis was performed with erythroid (Ery4 and Ery5) and megakaryocyte 
(Mega2) gene sets obtained from the studies of (Novershtern et al., 2011). Left panel: genes that 
were ≥2-fold upregulated in GATA1s-expressing cells as compared to wild-type GATA1-
expressing cells. Right panel: genes that were ≥2-fold downregulated in GATA1s-expressing cells 
as compared to GATA1-expressing cells. Genes were ranked according to their correlation with 
either the erythroid, “Ery”, phenotype (red) or megakaryocyte, “Meg”, phenotype (blue). The left 
panel shows that genes upregulated in GATA1s-expressing cells were significantly enriched for 
megakaryocyte genes. The right panel shows that genes downregulated in GATA1s-expressing 
cells were significantly enriched in erythroid genes. ES, enrichment score. 
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Figure 5.5. Absent erythropoiesis from iPSCs harboring GATA1s mutations. 
(A) Hematopoietic differentiation protocol. (B) Flow cytometry analysis showing CD34+/-
43+235+41+ progenitors within total embryoid body (EB) cultures on day 7 of hematopoietic 
differentiation and (C) suspension cells released from EBs on day 12 showing mature 
hematopoietic lineages: erythroid (CD41-235+), megakaryocytic (Meg, CD41+42+), and myeloid 
(CD45+18+). (D) Frequency of CD43+41+235+ progenitor cells in EB cultures on day 7-8 of 
hematopoietic differentiation. (E) Summary of distribution of lineage-committed cells in EB 
suspension cultures at day 12-14 of differentiation. (F) Morphology of hematopoietic cells in day 
20 differentiation cultures.  
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